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OBJECTIVE — To observe the implementation of American Diabetes 
Association (ADA) guidelines for care of type 2 diabetics at Peripheral 
Diabetes Clinics (PDCs) in Karachi, Pakistan. 
 
RESEARCH DESIGN AND METHODS — The study was performed using 
a retrospective medical chart review of 691 type 2 diabetic patients 20 
years of age and older. All of these patients had a definitive diagnosis of 
type 2 diabetes and records were documented on their first visit. Four 
peripheral diabetes clinics in four townships of Karachi district which were 
in operation between 1 Jan 2005 to 29 Dec 2006 were selected. 
 
RESULTS — A total of 691 patients (332 males and 359 females) with 
type 2 diabetes had a mean age of 50.94 ±10.4 years. Mean BMI was 
26.6 ± 4.77 kg/m2 and 60% of these patients had a positive family history 
of diabetes. Comorbidities were largely present, 84.6% had 
hyperlipidemia, 59% were hypertensive, 31.3% had retinopathy, 22.6% 
had nephropathy and 18.6% had peripheral neuropathy.  
 
On their first visit 86% had their blood pressure measured, 56% patients 
had serum creatinine measured, 45% had HbA1c measured, 31% patients 
had dilated eye examinations, and 25% had urine albumin screening. Of 
these patients, 44% had lower leg examination and 2% patients were 
suffering from diabetic foot ulcer.  
 
Mean systolic blood pressure (SBP) was 138 ± 19.8 mm Hg, mean 
diastolic blood pressure (DBP) was 85.58 ± 9.6 mmHg. Mean fasting blood 
glucose levels was 194.32 ± 70.59 mg/dl, random blood glucose levels 
was 278.86 ± 100.75 mg/dl and mean HbA1c levels was 9.13 ± 1.6%. 
Mean cholesterol levels was 194.15 ± 42.79 mg/dl, mean triglyceride 
levels was 224 ± 118.12 mg/dl, HDL cholesterol levels was 39.16 ± 7.1 
mg/dl and LDL cholesterol levels was 117.62 ± 31.16 mg/dl.  
 
Management of type 2 diabetic patients was complex: 41% of patients on 
antiplatelet therapy; 27% on anti-hypertensive; 22% on insulin (includes 
Oral Hypoglycemic Agent + Insulin); 20.3% on angiotensin converting 




Family physicians were not adequately following the ADA recommended 
guidelines for comprehensive management of diabetes patients. 
Inadequate documentation of medical records may reflect poor diabetes 
care and comorbid conditions of hypertension and hyperlipidemia were not 
optimally managed according to ADA guidelines. In short, a wide gap 
exists between practice recommendations and delivery of diabetes care by 
peripheral diabetes clinics. 
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1.1 PAKISTAN - A BRIEF COUNTRY PROFILE 
Pakistan is the sixth most populous country in the world and has one of 
the largest Muslim populations in the world (1). It is a poor developing 
country situated in South Asia. 
A brief overview of the country is given below: 
 
A Brief Country Profile:  
Full name: Islamic Republic of Pakistan 
Term for Citizen(s): Pakistani 
Independence: August 14, 1947, from Britain 
Flag: Pakistan’s flag is green with a narrow vertical white band on its left 
side. A white crescent and star are in the center of the green band. Green 
signifies the Muslim majority, white denotes minorities, the crescent 
represents progress, and the star symbolizes light and knowledge. (2) 
Population: 164.7 million  
Capital: Islamabad 
Largest city: Karachi 
Area: 796,095 sq km (307,374 sq miles), excluding Pakistani- 
administered Kashmir (83,716 sq km/32,323 sq miles)  
Male life expectancy at birth (years) 62.7  
Female life expectancy at birth (years) 64.8  
Infant mortality rate (per 1000 live births) 68.8  
Under five mortality rate (per 1000 live births) 98.0 (2005)  
Maternal mortality ratio (per 10000 live births) 350.0 (2005)  
% Population growth rate 1.8 in 2007 
% Population below 15 years 36.9 in 2007  
% Population 65 years and over 4.3 in 2007  
Total Fertility Rate: 3.71 children born/woman in 2007  
Population below poverty line: 24% (Fiscal Year 05/06)  
Literacy rate: age 15 and over can read and write  
Male: 63% / Female: 36% / Total: 49.9% in 2005  
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People: Punjabi (66%), Sindhi (13%), Pakhtun, (10.9%), Muhajir - 
immigrants from India at the time of partition and their descendants 
(7.6%), Balochi (2.5%) 
Official languages: English and Urdu 
Languages spoken: Punjabi, Sindhi, Pashto, Urdu, Balochi, English and 
many other local languages 
Religions: Islam (97%), Hinduism, Christianity and others (3%) 
Monetary unit: 1 Pakistani Rupee (PKR) = 100 paisa  
Main exports: Textile products, rice, cotton, leather goods, carpets, 
sports goods, handi-crafts, fish and fruit 
GNI per capita: US $690 (World Bank, 2006)  
Major Political Parties: Pakistan Muslim League - Quaid-i-Azam (PML-
Q); Pakistan People's Party (PPP); Muttahida Majlis-i-Amal (MMA) (a 
coalition which includes the Jamaat-e-Islami and the Jamiat-Ulema-
Islami) ; Pakistan Muslim League - Nawaz (PML-N); Muttahida Qaumi 
Movement (MQM); and Awami National Party (ANP) 
Head of State: President Pervez Musharraf 








Pakistan shares borders with four countries: India to the east, China to 
the north east, Iran to the south west and Afghanistan along the western 
and northern boundaries. Pakistan's coastline on the Arabian Sea is 1,064 
km long. Total area of Pakistan is 803,940 sq km of which land is 778,720 
sq km & water is 25,220 sq km.  
The climate can be roughly split into 3 seasons: cool (October through 
February), hot (March through June), and wet (July through September). 
There are, however, significant regional variations. 
Pakistan is divided into four provinces: Balochistan, the North West 
Frontier Province (NWFP), Punjab and Sindh. In addition to the 4 
provinces there are also the Federally Administered Tribal Areas (FATA), 
the Federally Administered Northern Areas (FANA), and the Islamabad 
Capital Territory. Pakistan-administered Kashmir is known in Pakistan as 




Pakistan was part of British India prior to partition in 1947 and has a long 
history of settlement and civilization including the Indus Valley Civilization. 
The region has been invaded by the Greeks, Persians, Arabs, Afghans, 
Turks and Mongols. The territory was incorporated into British India in the 
nineteenth century. Since its independence on 14 Aug 1947, the country 
has been characterized by periods of military and economic growth 
interspersed with political instability (1).  
 
1.1.3 People:  
Pakistan has a large, mostly rural population with a high rate of growth. 
Population is estimated to be 164,741,000 as of 2007.  According to 
Pakistan’s 1998 census the population is clustered in the eastern 
provinces of Punjab and Sindh, which contain 78.6 percent of the total 
population mainly in the rural area. Only Sindh had roughly equal rural 
and urban populations (51.2 percent and 48.8 percent, respectively).  
The five main ethnic groups are Punjabi (66%), Sindhi (13%), Pashtun, 
(10.9%), Muhajir - immigrants from India at the time of partition and 
their descendants (7.6%), and Balochi (2.5%)  
Languages mainly spoken are Punjabi, Sindhi, Pashtun, Urdu, Balochi, 
English and many other local languages. (2) 
 
1.1.4 Population Demography:   
Pakistan’s fast-growing population has a substantial proportion of youths.  
According to 2007 estimates, 37% of the country’s population is less than 
14 years of age. Around 58.8% of the population is between 15-64 years 
while 4.3% of the population is 65 years or above. The overall median age 
is around 20.9 years while it is 20.7 years for males and 21 years for 
females.  
Sex ratio is 1.045 male(s)/female for the total population.  
Life expectancy at birth for the total population is 63.75 years. It is 62.73 
years for males and 64.83 years for females.   
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Infant mortality rate (per 1000 live births)   68.8  
Under five mortality rate (per 1000 live births)  98.0 (2005) (6) 
Maternal mortality ratio (per 10000 live births)  350.0 (2005) (6) 
% Population growth rate      1.8 (2007) 
% Population below 15 years     36.9 in 2007  
% Population 65 years and over     4.3 in 2007  
Population growth rate:      1.828%  
Total Fertility Rate:   3.71 children born/woman (2007)  
Birth rate:    27.52 births/1,000 population  
Death rate:   8 deaths/1,000 population (5, 3) 
 
1.1.5 Education: 
50% of the adult population is illiterate. Pakistan has low indicators of 
educational attainment, and education has been under funded for 
decades. Free primary education is a constitutional right and is 
compulsory in every province except Balochistan (5). Education in 
Pakistan is divided into five levels: primary (grades one through five); 
middle (grades six through eight); high (grades nine and ten, leading to 
the Secondary School Certificate); intermediate (grades eleven and 
twelve, leading to a Higher Secondary school certificate); and university 
programs leading to graduate and advance degrees. Pakistan also has a 
parallel secondary school education system in private schools, which is 
based upon the curriculum set by the University of Cambridge. Some 
students choose to take O level and A level exams, which are 
administered by the British Council, in place of government exams.  All 
academic education institutions are the responsibility of the provincial 
governments. The federal government mostly assists in curriculum 
development, accreditation and some financing of research (1). In 
addition to public and private schools, an indeterminate number of 
mosque-administered madrassas provide free room, board, and 




Pakistan’s economy depends mostly on agriculture. The GDP - per capita 
(PPP) of the country is $2,600 according to 2006 estimates. 
Unemployment rate is 6.5% plus substantial underemployment while 24% 
of the population lives below poverty line. Poverty line is the minimum 
level of income deemed necessary to achieve an adequate standard of 
living. Definition of poverty varies considerably amongst nations and the 
definition of poverty line is significantly higher in developed nations than 
in developing nations. Here it is taken as one US dollar. (3) 
An earthquake measuring 7.6 struck northern Pakistan on 8 October 
2005. The tremors were felt as far away as India and Afghanistan. The 
earthquake affected 3.5 million people and cost the lives of over 75,000 
people in the region. Almost 2.5 million people have lost their homes. This 
natural disaster also badly affected the financial resources of the country. 
Pakistan with great help from the international community has moved 
from emergency relief to long-term reconstruction and rehabilitation of 
the affected area. (5) 
 
1.1.7 Politics 
Parliament consists of two Houses i.e., the Senate (Upper House) and the 
National Assembly (Lower House).  The Senate is a permanent legislative 
body and symbolises a process of continuity in the national affairs. It 
consists of 100 members. The four Provincial Assemblies, Federally 
Administered Tribal Areas and Federal Capital form its electoral college.   
The National Assembly has a total membership of 342 elected through 
adult suffrage (272 general seats, 60 women seats and 10 non-Muslim 
seats) (7).  
Each province has a governor appointed by the president, and provinces 
also have an elected legislative assembly and a chief minister who is the 
leader of the legislative assembly’s majority party or coalition. The chief 
minister is assisted by a council of ministers chosen by the chief minister 
and formally approved by the governor. Federally administered areas also 
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have their own legislative entities, which have had less autonomy from 
the federal government than provincial legislatures. (2) 
Following the assassination of popular opposition leader Benazir Bhutto, 
general elections were held in Pakistan on 18 Feb, 2008 to elect members 
of the national assembly of Pakistan.  Pakistan’s two main opposition 
parties, the Pakistan Peoples Party (PPP) and the Pakistan Muslim League 
- Nawaz (PML (N)) won majority of seats in the election, although the 
Pakistan Muslim League –Quaid e Azam (PML (Q)) was actually second in 
popular vote. The PPP and PML (N) are to form the new government (1). 
 
1.1.8 Lifestyle and Physical Activity 
According to rural and urban settings the lifestyle of the Pakistani people 
is different. The rural culture favors a labor-intensive lifestyle. In the rural 
areas apart from household work the women also help their men in the 
fields and in looking after the livestocks. Lifestyle changes that occur due 
to urbanization are leading more people to have sedentary occupations 
with insufficient physical activity. This is one of the reasons why we are 
seeing the burden of obesity in the form of Diabetes on most world 
population. The urban Pakistani culture also does not favour doing extra 
physical exercise apart from the requirements of the daily chores.  
The traditional Pakistani diet is spicy with excessive oil and is another 
contributing factor to obesity and later in life to diabetes. The staple 
Pakistani food is wheat and “Roti” – a kind of bread made from flour is 
usually taken with all meals. The type of food consumed by the population 
generally depends on their socioeconomic status, occupation and level of 
physical activity. The people in the city have high caloric intake and prefer 
to eat meat mostly beef, mutton and chicken. The nutrient importance of 
fruits and vegetables is generally not taken into consideration while 
presenting a meal. Large amount of carbohydrates and fats are consumed 




1.1.9 Health Care System 
Pakistan’s health indicators, health funding, and health and sanitation 
infrastructure are generally poor, particularly in rural areas. About 19 
percent of the population is malnourished—a higher rate than the 17 
percent average for developing countries—and 30 percent of children 
under age five are malnourished. Leading causes of sickness and death 
include gastroenteritis, respiratory infections, congenital abnormalities, 
tuberculosis, malaria, and typhoid fever.  
According to 2002 government statistics, there were 12,501 health 
institutions nationwide, including 4,590 dispensaries, 906 hospitals with a 
total of 80,665 hospital beds, and 550 rural health centers with a total of 
8,840 beds. (2) 
 
In 2003 
Health Expenditure indicators: 
GDP per capita 550 
Total expenditure on health of % of GDP 2.4  




Human and physical resources indicators: 
Physicians per 10000 population 8.0   
Dentists per 10000 population 1.00  
Nursing and midwifery personnel per 10000 population 3.0  
 
Coverage with primary health care services indicators: 
Population with access to local health services, total (%) 96   
Population with access to local health services, urban (%) 100   
Population with access to local health services, rural (%) 92   
Contraceptive prevalence rate (%) 34  
Antenatal care coverage (%) 41 (6) 
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1.2 BACKGROUND: 
Diabetes Mellitus (DM) is a leading cause of death and disability. 
Improvement of the quality of diabetes care is essential for reducing the 
incidence of diabetes complications. DM is a life long disease which places 
grave economic burden not only on the person having diabetes but also 
affects the patient’s family financially. In the past type 2 diabetes mellitus 
(T2DM) was assumed to be a disease of the rich man and usually striking 
someone after 40 years of age. But now with the great change in lifestyles 
(unhealthy diet and lack of physical activity) and urbanization, T2DM is 
emerging in a much younger age group and in some parts of the world 
even among children as young as 8 years of age. T2DM is being reported 
in children from the United States, Canada, Japan, Hong Kong, Australia, 
New Zealand, Libya, and Bangladesh. (8) 
 
1.2.1 Diabetes Mellitus  
Diabetes mellitus is a chronic condition that arises when the pancreas 
does not produce enough insulin or when the body cannot effectively use 
the insulin produced or both. This causes hyperglycemia (an abnormally 
high concentration of glucose in the blood), which seriously damages 
many of the body’s systems, especially the blood vessels and nerves. 
There are two basic forms of diabetes: type 1 and type 2. People with 
type 1 diabetes do not produce insulin as a result of autoimmune 
destruction of beta cells. People with type 2 diabetes produce insulin but 
cannot use it effectively. (9) Symptoms of marked hyperglycemia include 
polyuria, polydipsia, weight loss, sometimes with polyphagia, and blurred 
vision. Impairment of growth and susceptibility to certain infections may 
also accompany chronic hyperglycemia. (10)  
 
1.2.2 Global Burden of Diabetes Mellitus 
Diabetes is one of the most costly diseases ever in both human and 
economic terms. Chronic diseases are the largest cause of death in the 
world led by cardiovascular disease (17 million deaths in 2002, mainly 
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from ischemic heart disease and stroke) and followed by cancer (7 million 
deaths), chronic lung diseases (4 million), and diabetes mellitus (almost 1 
million). (11) In 2003, the International Diabetes Federation (IDF) 
estimated that almost 200 million people around the world had diabetes. 
By 2025 this figure is expected to rise to 333 million, amounting to 6.3% 
of the world’s population living with diabetes. (12) In developing 
countries, the number of people with diabetes will increase by 150% in 
the next 25 years. (13) In developed countries most people with diabetes 
are above the age of retirement, whereas in developing countries those 
most frequently affected are between 35 and 64 years of age.  (13) 
Almost 50% of people with T2DM are not aware that they have the 
condition. India and Pakistan are in the world’s top 10 in terms of the 
highest number of people with diabetes in 2003 (respectively 35.5 million 
and 6.2 million), highest projected number of people with diabetes in 
2025 (respectively 73.5 and 11.6 million), and highest current and 
projected number of people with impaired glucose tolerance. (14) Article 
25 of the Declaration of Human Rights states that: ‘everyone has the right 
to a standard of living adequate for the health and well-being of himself 
and of his family, including medical care.’ This basic human right is a 
luxury that many especially in the developing world cannot afford. (15) 
 
In Pakistan alone:- 
♦ The IDF gives an estimate of 12% prevalence in Pakistan, with a total of 
8.8 million people with diabetes in 2000. (16) 
♦ It is estimated that 6.2 million people have diabetes, representing 8.5 % 
of the adult population. (12) 
♦ According to WHO, the number of people with diabetes in Pakistan 
during 1995-2025 is expected to be about 14.5 million (17). While over 
the next 10 years according to WHO death from diabetes in Pakistan is 
expected to increase by 51%.  (18) 
♦ The high economic burden of diabetes in the Eastern Mediterranean and 
Middle East (EMME) Region is due to the high prevalence rate coupled with 
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the high cost of diabetes care and limited resources. A less affluent 
country such as Pakistan is estimated to spend between 430 and 800 
million dollars on diabetes care.  (12) 
Total monthly expenditures of an average Pakistani household is Rs. 8965 
(149 USD), food, clothing and housing, consuming nearly 80% of it. Rs. 
260 (4.3 USD) per month (2.9% of the total monthly expenditure) is 
spent on health reflecting low priority of healthcare. Prevention of 
diabetes and its complications therefore, is the main stay of diabetes care. 
(19) 
 
1.2.3 Diabetes Care in Pakistan 
It is estimated that in Pakistan 6.2 million people have diabetes, 
representing 8.5 per cent of the adult population in Pakistan. According to 
the World Health Organization (WHO), the figure is expected to reach 11.6 
million by 2025. (20) 
Institutions specializing in diabetes care are limited in number and are 
concentrated in the big cities. There are no support personnel and very 
few dietitians. The government faces a major challenge to provide 
healthcare for everyone especially when 69% of the population lives in 
rural area. Health facilities are concentrated in the urban areas and the 
major services are provided by the private sector. (21)  
In Pakistan, less than one percent of public expenditure is spent on health 
and only 20% of health services are provided by the public sector. The 
result is an ever-increasing gap between availability of services and the 
population’s needs. The private sector plays a major health-care role in 
Pakistan. The private sector supplies >80% of outpatient healthcare and 
therefore is a critical resource in efforts to provide accessible, affordable 
and equitable services. Pakistan’s private sector remains largely absent 
from the health policy table, although there are hopeful signs that this 
may be changing. The 1995 National Action Plan for health placed special 
emphasis on diabetes and was designed to ensure the provision of this 
care. However, the Plan was not fully implemented. 
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Until several years ago, there was no healthcare facility in Pakistan which 
offered comprehensive care to the diabetics under one roof. Private sector 
has now taken the lead as Baqai Medical University in Karachi in 1997 
established Baqai Institute of Diabetology and Endocrinology (BIDE). It 
was first such center in Pakistan offering most comprehensive diabetic 
care by multidisciplinary team comprising of apart from the diabetologists 
of dietitians and diabetes educators. In 1999, BIDE started one year 
diploma in diabetology with the aim to train family physicians in primary 
diabetes care. All over Pakistan BIDE was the first to set up a special foot 
clinic for diabetes. In 2006 to improve diabetes care especially foot care in 
low resource and underserved communities in Pakistan, BIDE became a 
member of international working group on diabetic foot (IWGDF). This 
year in 2008 a diploma course for diabetes educators was commenced to 
create further diabetes awareness among healthcare providers and 
general public. 
In the public sector, Jinnah Postgraduate Medical Center (JPMC) in 
Karachi, Mayo Hospital and Services Hospital in Lahore have diabetes 
centers and many other Non Governmental Organizations (NGOs) are also 
running diabetes clinics. The Dow University of Health Sciences (DUHS) in 
Jan 2008 established the National Institute of Diabetes and Endocrinology 
(NIDE) at the Ojha campus of the varsity. This institute in the public 
sector has now entered its second phase of outdoor patients where 
consultation is free. It has facility for laser therapy to prevent blindness in 
diabetics which is available at discounted rates.  
 
1.2.4 Complications of Diabetes 
Aggressive management of hyperglycemia, hypertension, dyslipidemia 
and other risk factors can prevent many complications of diabetes. 
Diabetes complications are common and almost triple the annual cost of 
managing diabetes. The long term complications of diabetes are: 
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Arteriosclerosis, diabetic retinopathy, diabetic nephropathy, diabetic 
neuropathy, heart disease, stroke, peripheral vascular disease and 
diabetic foot ulcer. 
These complications have been further grouped as microvascular and 
macrovascular complications. 
 
1.2.4.1 Microvascular complications: 
Control of hyperglycemia (target fasting blood glucose level <110 mg/dl, 
target HbA1c level ≤7%) and hypertension (target blood pressure 
≤130/80 mm Hg) prevents microvascular complications in diabetes. 
Microvascular complications include: 
i) Diabetic Retinopathy: 
Diabetic retinopathy is often asymptomatic in its most treatable stages. 
Unfortunately, only about half of persons with diabetes receive adequate 
eye care. Early detection of diabetic retinopathy is critical. Diabetes 
accounts for 12,000 - 24,000 of new cases of blindness annually and is 
the leading cause of new cases of blindness in adults age 20 - 74. The 
most common eye disorder in diabetes is retinopathy. People with 
diabetes are also at higher risk for developing cataracts and certain types 
of glaucoma. Retinopathy is a condition in which the retina in the eye 
becomes damaged. The two primary abnormalities that occur are a 
weakening of the blood vessels in the retina and the obstruction in the 
capillaries -- probably from very tiny blood clots. Tight control of blood 
pressure can also help protect against retinopathy. Aspirin therapy does 
not help prevent retinopathy. (22) 
ii) Diabetic Nephropathy:  
The earliest sign of diabetic renal disease is the presence of subclinical 
increases in urinary albumin excretion, termed microalbuminuria (urinary 
albumin excretion rate, 30–300 mg/24 hrs). The tiny filters in the kidney 
(called glomeruli) become damaged and leak protein into the urine. Over 
time this can lead to kidney failure. Urine tests showing microalbuminuria 
(small amounts of protein in the urine) are important markers for kidney 
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damage. Diabetic nephropathy occurs in about 20 - 40% of patients with 
diabetes and represents a distinct clinical syndrome characterized by 
albuminuria, hypertension, and progressive renal insufficiency. Diabetic 
nephropathy can lead to end-stage renal disease (ESRD), a serious 
condition in which a patient's survival depends on either dialysis or kidney 
transplantation. (22) 
iii) Diabetic Neuropathy: 
Persons with diabetes who develop neuropathy may have no symptoms or 
may experience pain, sensory loss, weakness, and autonomic dysfunction.  
The two main types of neuropathy are: 
a) Peripheral (affects nerves in the toes, feet, legs, hand, and arms) and 
b) Autonomic (affects nerves that help regulate digestive, bowel, bladder, 
heart, and sexual function). 
Peripheral neuropathy particularly affects sensation. The most serious 
consequences of neuropathy occur in the legs and feet and pose a risk for 
ulcers and, in very severe cases, amputation. Peripheral neuropathy 
usually starts in the fingers and toes and moves up to the arms and legs 
(called a stocking-glove distribution). Symptoms include: 
• Tingling  
• Weakness  
• Burning sensations  
• Loss of the sense of warm or cold  
• Numbness (if the nerves are severely damaged, the patient may be 
unaware that a blister or minor wound has become infected)  
• Deep pain 
In some cases, neuropathy may mask angina, the chest pain warning for 
heart disease and heart attack. Patients with diabetes should be aware of 
other warning signs of a heart attack, including sudden fatigue, sweating, 
shortness of breath, nausea, and vomiting. If diabetes affects the nerves 
in the autonomic nervous system, then abnormalities of blood pressure 
control and bowel and bladder function may occur. In men, erectile 
dysfunction (impotence) is also associated with neuropathy. (22) 
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iv) Diabetic Foot Ulcer: 
Foot ulcers and amputations are a major cause of morbidity for people 
with diabetes. Risk factors for these complications are the presence of 
peripheral neuropathy, altered biomechanics in the foot and peripheral 
vascular disease. About half of all lower-limb amputations in people with 
diabetes are preventable. An estimated 15% of patients with diabetes 
experience serious foot problems. They are the leading cause of 
hospitalizations for these patients. According to a 2005 study in the 
Lancet, every 30 seconds someone in the world receives a lower limb 
amputation due to diabetes. About 85% of amputations start with foot 
ulcers, which develop in about 12% of people with diabetes. Foot 
infections often develop from injuries. Even minor infections can develop 
into severe complications. Numbness from nerve damage, which is 
common in diabetes, compounds the danger since the patient may not be 
aware of injuries. About one-third of foot ulcers occur on the big toe. A 
2003 government survey found that those at higher risk for foot ulcers 
tend to be people with diabetes who are overweight, smokers, and those 
with a long history of diabetes. People who have the disease for more 
than 20 years and are insulin-dependent are at the highest risk. Related 
conditions that put people at risk include peripheral neuropathy, 
peripheral artery disease, foot deformities, and a history of ulcers. (22) 
 
1.2.4.2 Macrovascular complications: Preventing these complications 
in T2DM which is often associated with other cardiovascular risk factors, is 
a major challenge. They include: 
i) Coronary Heart Disease (CHD) and Stroke: Heart attacks account 
for 60% and strokes for 25% of deaths in patients with diabetes. Diabetes 
speed the progression of arteriosclerosis (hardening of the arteries). 
Diabetes can adversely affect blood lipid levels by lowering high density 
lipoprotein -HDL ("good cholesterol") and increasing triglycerides. This can 
lead to coronary artery disease, heart attack, or stroke. According to a 
2007 study, the risk of stroke doubles within 5 years of type 2 diabetes 
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diagnosis. Impaired nerve function (neuropathy) associated with diabetes 
also causes heart abnormalities. Some experts estimate that the mortality 
rates from neuropathy-related heart conditions range between 15 - 53%.  
Women with diabetes are at particularly high risk for heart problems. A 
2007 study indicated that while progress has been made in reducing 
mortality rates among men with diabetes, women with diabetes continue 
to face a high risk of death from heart disease and overall causes. Tight 
blood sugar control may help protect blood vessels and reduce the risk for 
blood clotting. Taking a daily aspirin (75 - 162 mg/day) reduces the risk 
for blood clotting and may help protect against heart attacks and heart 
disease. In a 2000 study, low-dose aspirin was associated with a 30% 
lower risk for death from heart disease in adults with type 2 diabetes. 
Patients should strive for blood pressure levels of less than 130/80 mm Hg 
(systolic/diastolic). (Controlling systolic pressure may be especially 
important for reducing the risk for kidney complications.) 
ii) Peripheral Vascular Disease (PVD):  
People with peripheral vascular disease (PVD) may or may not have 
symptoms. Because of silent symptoms, many cases of PVD go 
undiagnosed. This condition is also called as peripheral arterial disease 
(PAD) and occurs when atherosclerosis affects arteries in the feet and legs 
or much less commonly the hands and arms. In such cases the arteries 
become blocked, obstructing oxygen-rich blood flow. PAD is now 
recognized as a major risk factor for heart disease and stroke. 
Claudication is crampy leg pain that occurs during exercise, especially 
walking. The pain is due to insufficient blood flow in the legs (caused by 
blocked arteries). Intermittent means the pain comes and goes. 
Intermittent claudication is the most prominent symptom of PAD. The 
most frequently affected artery in intermittent claudication is the popliteal 
artery. People with T2DM have three to four times the usual risk for PAD 
and intermittent claudication. They also tend to develop PAD at earlier 
ages and suffer more severe cases. In one study it was found that people 
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with diabetes and intermittent claudication had 30% chance of developing 
skin ulcers in their legs. (22) 
 
Other diabetes related complications include: 
Mental Function and Dementia 
Studies indicate that patients with type 2 diabetes face a higher than 
average risk of developing dementia caused either by Alzheimer's disease 
or problems in blood vessels in the brain. Problems in attention and 
memory can occur even in people under age 55 who have had diabetes 
for a number of years. 
 
Depression 
Diabetes doubles the risk for depression. Furthermore, according to one 
study, depression, in turn, increases the risk for hyperglycemia and 
complications of diabetes.  
 
Infections 
People with diabetes face a higher risk for influenza and its complications, 
including pneumonia, possibly because the disorder neutralizes the effects 
of protective proteins on the surface of the lungs. In fact, deaths among 
people with diabetes increase by 5 - 15% during flu epidemics. Everyone 
with diabetes should have annual influenza vaccinations and a vaccination 
against pneumococcal pneumonia. Women with diabetes face a 
significantly higher risk for urinary tract infections, which are likely to be 
more complicated and difficult to treat than in the general population. 
 
Diabetes increases the risk for other conditions, including: 
• Hearing loss  
• Periodontal disease  
• Carpal tunnel syndrome  
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• Nonalcoholic fatty liver disease, also called nonalcoholic 
steatohepatitis (NASH), a particular danger for people who are 
obese.  
• Colorectal cancer  
• Uterine cancer  (22) 
 
1.2.5 American Diabetes Association (ADA):- 
The American Diabetes Association was founded in 1940 as a scientific 
and medical organization serving people with diabetes. The mission of the 
ADA is to prevent and cure diabetes and to improve the lives of all people 
affected by diabetes. To fulfill this mission, the ADA funds research, 
publishes scientific findings, provides information and other services to 
people with diabetes, their families, health professionals and the public. 
The Association is also actively involved in advocating for scientific 
research and for the rights of people with diabetes. The ADA writes 
standards of medical care for people with diabetes. These guidelines give 
doctors the most up-to-date information on caring for their patients with 
diabetes. (23) 
 
ADA Recommendations for Adults with T2DM:-  
Diabetes is a chronic illness that requires continuing medical care and 
patient self-management education to prevent acute complications and to 
reduce the risk of long-term complications. Every year, ADA issues Clinical 
Practice Recommendations, a series of updated recommendations, to help 
health care providers treat people with diabetes using the most current 
research available.  
The ADA 2004 recommendations for Adults with T2DM have been applied 
for this study. 
Glycemic Control: 
Biochemical Index  Normal  Goal   Additional Action Suggested 
Pre-prandial glu (mg/dl) < 110  80-120   <80; >140 
Bedtime glu (mg/dl)    < 120  100-140   <100; >160 
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Hemoglobin A1c (%)   < 6   < 7    > 8 
Order of priorities for treatment of diabetic dyslipidemia in adults: 
Low-Density Lipoprotein (LDL) < 100 mg/dl 
< 70 mg/dl *very high risk patients 
Triglycerides (TGs) ≤ 150 mg/dl 
Total cholesterol (TCs) ≤ 200 mg/dl 
High-Density Lipoprotein (HDL) > 40 mg/dl in men 
> 50 mg/dl in women 
Hypertension goals in DM 
Blood pressure (BP) ≤ 130/80 mmHg 
 
Assessment of Glycemic Control 
Recommendations: 
– Perform glycosylated hemoglobin A1c (HbA1c) at least two times/year in 
patients who are meeting treatment goals 
- Perform HbA1c quarterly in patients not meeting glycemic goals 
 
Management of Diabetes Complications 
Cardiovascular Disease (CVD) 
♦Patients > 55 years, ± Hypertension (HTN) with another Cardiovascular 
(CV) risk factor: 
Angiotensin-Converting Enzyme Inhibitors (ACEI) should be considered to 
reduce risk of CV events 
♦ All patients with diabetes and HTN should be treated with ACEI or 
Angiotensin II Type 1 Receptor Blockers (ARB) 




For lipid disorders: 
♦ Lipid profile at least annually and more often if needed 
If LDL < 100, HDL > 50, and TG’s < 150: 
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Primary goal: 
Lower LDL < 100 mg/dl 
Patients > 40 years of age with TC ≥ 135 mg/dl, without overt CVD: 
LDL reduction of 30 – 40 % regardless of baseline is recommended 
Very high risk patients: 
♦ Acute Coronary Syndrome or previous CV events 
♦ More aggressive therapy to achieve LDL < 70 mg/dl may lead to a 
significant reduction in further events. 
 
Albumin Excretion: 
Category     Spot collection (microgms/mg creatinine) 
Normal      < 30 
Microalbuminuria    30-300 
Clinical albuminuria    > 300 





Acetylsalicylic acid (ASA) therapy (75-162 mg/d) in diabetes patients with 
increased CV risk: 
♦ Age > 40 






ASA therapy (75-162 mg/day) in diabetes patients with: 
♦ History of Myocardial Infarction (MI) 
♦ Vascular bypass procedure 
♦ Stroke or Transient Ischemic Attack (TIA) 
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♦ PVD 
♦ Intermittent Claudication 
♦ Angina 
Should not be recommended: 
Age < 21 




Perform test annually for presence of Microalbuminuria 
Nephropathy treatment 
T2DM, HTN, microalbuminuria, and renal insufficiency: 
ACEI and ARBs delay the progression to macroalbuminuria  
T2DM, HTN, macroalbuminuria, and renal insufficiency: 




Initial dilated and comprehensive eye exam shortly after diagnosis of 
diabetes 
Subsequent examinations should be repeated annually.  (24) 
Use of anti-platelet agents, statins and ACE inhibitors to treat T2DM with 
and without symptomatic atherosclerosis showed a reduction in CV risk 
and mortality.  (25)  
 
However, few studies have focused on specialist practice but it is unclear 
whether specialists were able to meet ADA guidelines. (26, 27) In order to 
achieve an optimal care for diabetic patients, BIDE has initiated a program 
to train physicians as Associate Diabetologists (ADs) to support the 
Peripheral Diabetes Clinics (PDCs) with a view to improve quality of care. 
It is thought that such early intervention can translate into better 
metabolic control and, ultimately, the prevention of diabetes 
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complications.  But it is not known whether the new training program has 
impacted on the quality of care rendered to the diabetic patients. 
Family Physicians (FPs) as the primary care providers play a key role in 
the diagnosis and treatment of health problems in the community. The 
study analyzed the impact of primary diabetes care given at PDCs by 
trained ADs from BIDE at their clinical practice. Furthermore, the purpose 
of this study was to examine the level of diabetes care provided to the 
population coming to PDCs in Karachi, Pakistan. 
 
1.3 RATIONALE OF THE STUDY 
Several studies involving physician surveys, chart audits and reviews of 
administrative databases have shown that the quality of diabetes care by 
primary care physicians (PCPs) is suboptimal. (28, 29, 30, 31) T2DM is 
frequently not diagnosed until complications appear, and approximately 
one-third of all people with diabetes may be undiagnosed. (24) Long-term 
complications of diabetes include retinopathy with potential loss of vision; 
nephropathy leading to renal failure; peripheral neuropathy with risk of 
foot ulcers, amputation, and Charcot joints; and autonomic neuropathy 
causing gastrointestinal, genitourinary, and cardiovascular symptoms and 
sexual dysfunction. (32) Therefore, early identification and treatment of 
these diabetes complications may reduce the severity of the 
complications.  
As part of a program to reduce these long-term complications at primary 
preventive care level, the study will determine how frequently assessment 
of cardiovascular risk factors, fundoscopic examinations, (referral to an 
ophthalmologist) and foot examinations are provided to T2DM patients. 
(33) Studies have shown that complications of diabetes can be slowed or 
prevented by better management on the part of the health care team and 
patient. (34) A single study used computerized data records from three 
managed care organizations to assess the prevalence of HbA1c tests,
 
dilated eye examinations, and urine protein assessments (both 
microalbuminuria and macroalbuminuria) in patients with diabetes. (35) 
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Despite its high prevalence, serious long term complications, and 
established evidence-based guidelines for management (24, 36), 
translation of practice recommendations to care is still deficient in Asian 
(37) and developed countries (38, 39, 40).  
The primary care sector is of key importance for the management of 
patients with diabetes mellitus. With this in view, BIDE started training 
FPs nine years ago with an aim to deliver primary diabetes care to the 
common man, and to establish a network of PDCs across the country.  
A study similar to our study has not been done in the South Asia region. It 
was hoped that the outcome of this study will show us what measures are 
further needed to improve the quality of care given to T2DM patients. As 
we know that early diabetic management can delay worsening of already 
established complications, therefore, we can evaluate the specialized 
diabetic management training being offered at these PDCs. If necessary in 
the long run even recommend local diabetic guidelines most appropriate 
for the local ethnic population. 
 
1.4 LITERATURE REVIEW  
 
Diabetes mellitus is now recognized as one of the major health problem 
facing the country. The prevalence of diabetes mellitus in Pakistan is high, 
12% of people above 25 years of age suffer from the condition (41). 
Majority of those suffering from diabetes mellitus have T2DM and its 
related complications. T2DM is an important cause of morbidity and 
mortality. Looking after and managing this increased pool of diabetics will 
seriously affect the health services. This issue must be given a serious 
thought by our health planners and all others concerned with health 
delivery system in Pakistan. Prevalence of T2DM is increasing dramatically 
because of population aging and sedentary lifestyle particularly in South 
Asia. (42, 43)  
A study was conducted in USA, using ADA guidelines to evaluate control of 
CVD risk factors by auditing the medical records of patients suffering from 
diabetes and hypertension. 90.9% had type 2 diabetes, and 26.7% met 
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the target BP 130/85 mmHg. A total of 35.5% met the goal LDL 
cholesterol level of <100 mg/dl, 26.7% had an HbA1c <7%, and 45.6% 
were on antiplatelet therapy. Only 3.2% of patients met the combined 
ADA goal for BP, LDL cholesterol, and HbA1c. (42) 
A cross sectional survey was conducted in India to evaluate the quality of 
care in known diabetic patients from the middle- and high-income group 
populace of Delhi. Thirty areas were selected for a house-to-house survey 
to recruit a minimum of 25 subjects (known diabetes ≥1 year; aged 35–
65 years) per area. Data were collected by interview, by blood sampling, 
and from medical records. A total of 819 subjects were enrolled and in 
total, 13.0% (95% CI 9.6 –17.3) of the patients had HbA1c estimation 
and 16.2% (13.5–19.4) had a dilated eye examination in the last year, 
32.1% (27.5–36.6) had serum cholesterol estimation in the last year, and 
17.5% (14.2–21.5) were taking aspirin. An estimated 42.0% (37.7– 46.2) 
had an HbA1c value >8%, 40.6% (36.5– 44.7) had an LDL cholesterol 
level >130 mg/dl, and 63.2% (59.6–66.6) had blood pressure 
levels >140/90 mmHg. The conclusion was that a wide gap exists 
between practice recommendations and delivery of diabetes care in Delhi. 
(43) 
A retrospective study was conducted in USA, to determine whether rural 
health care providers are compliant with ADA clinical practice guidelines 
for glycemic, blood pressure, lipid management, and preventative 
services. The medical records of 399 patients 45 years of age and older 
were reviewed, with a definitive diagnosis of diabetes seen for primary 
diabetes care at four rural health facilities in Montana between 1 January 
1999 and 1 August 2000. Glycemic testing was adequate (85%), and 
glycemic control (HbA1c 7.43 ± 1.7%) was above the national average. 
Comorbid conditions of hypertension and dyslipidemia were not as well 
managed. Mean systolic blood pressure (SBP) was 139 ± 18.8 mmHg and 
LDL was 119 ± 33 mg/dl. Of 399 patients, 11 were considered as needing 
no additional treatment based on ADA guidelines of an HbA1c level <7%, 
a BP <130/85 mmHg, and a LDL level <100 mg/dl. Monofilament testing 
 40
and dilated eye examinations were poorly documented, as were 
immunizations. (44) 
A study in USA was conducted to estimate the proportion of U.S. adults 
with diabetes who meet ADA clinical practice recommendations. Data from 
the 1999–2002 National Health and Nutrition Examination Survey was 
used to estimate the proportion of adults with diabetes meeting ADA 
recommendations for HbA1c, HDL cholesterol, LDL cholesterol, 
triglycerides, blood pressure, renal function and smoking. Among U.S. 
adults with diabetes in 1999–2002, 49.8% had HbA1c <7%; 27.4, 36.0, 
and 65.0% were classified as low risk for HDL cholesterol, LDL cholesterol, 
and triglycerides, respectively. Nearly 40% met blood pressure 
recommendations and 66% had normal renal function. The conclusion of 
the study was that achievement of ADA clinical practice recommendations 
is far from adequate in U.S. adults with diabetes. (45) 
Another study in USA was conducted to determine whether ADA guidelines 
can be met in the context of routine endocrinology practice. Charts were 
reviewed for a group of patients who were examined in 1998, followed for 
≥1 year, and had two or more visits during that year. Process measures 
and metabolic outcomes were studied for patients with T2DM. Of a total of 
121 patients with type 2 diabetes many had complications: 80% had 
hypertension, 64% had hyperlipidemia, 78% had neuropathy, 22% had 
retinopathy, and 21% had albuminuria. Management of type 2 diabetic 
patients was complex: 31% used oral hypoglycemic agents and insulin, 
and 26% used insulin alone; 42% of patients taking insulin therapy 
injected insulin three or more times per day. Within 12 months, 74% of 
patients had dilated eye examinations, 70% had lipid profiles, and 55% 
had urine albumin screening. Of the patients, 87% had a foot examination 
at their last visit. Blood pressure levels averaged 133/72 mmHg, 
cholesterol levels averaged 4.63 mmol/l, triglyceride levels averaged 1.99 
mmol/l, HDL cholesterol levels averaged 1.24 mmol/l, and LDL cholesterol 
levels averaged 2.61 mmol/l. Random blood glucose levels averaged 8.0 
mmol/l, and HbA1 c levels averaged 6.9 ± 0.1%. This study provided 
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evidence that ADA guidelines can be achieved in specialist practice. 
Although comorbidities and diabetes complications were frequent, patients 
with T2DM had good glycemic control. Most patients had appropriate 
screening examinations, and BP and lipid outcomes were also good. (46) 
 
1.5 OBJECTIVES OF THE STUDY 
 
1.5.1 General Objective 
The main aim was to determine if ADA recommended guidelines for 
diagnosis and care of diabetes taught to FPs during their diploma training 
in diabetology was implemented in their daily practice. If yes then to what 
extend.  
 
1.5.2 Specific Objectives 
(i) To observe any deviation from the ADA recommended guidelines 
related to risk assessments like: recording weight, smoking, BP control, 
measuring HbA1c values, lipid managements, conducting foot inspections, 
fundus examinations and monitoring for early diabetic nephropathy.  
 






























































2.1 Research Setting:- 
The research took place in Karachi, which is Pakistan’s largest 
cosmopolitan city with a population of more than 16 million. Karachi is the 
country's industrial center and the provincial capital of Sindh. It is located 
in the south of Pakistan, on the coast of the Arabian Sea and also has the 
largest port of the country. The metropolitan area along with its suburbs 
comprises the world's fourth most populated city, spread over 3,530 
square kilometers. (47) The city credits its growth to the mixed 
populations of economic and political migrants and refugees from different 
national, provincial, linguistic and religious origins that have largely come 
to settle here permanently.  
At present the City-District of Karachi is divided into 18 towns governed 
by elected municipal administrations. The towns are as:  
Baldia Town, Bin Qasim Town, Gadap Town, Gulberg Town, Gulshan Town, 
Jamshed Town, Keamari Town, Korangi Town, Landhi Town, Liaquatabad 
Town, Lyari Town, Malir Town, New Karachi Town, North Nazimabad 
Town, Orangi Town, Sadder Town, Shah Faisal Town and SITE Town. 
The towns are sub-divided into 178 localities governed by elected union 
councils (UC's). Each UC is a body of thirteen directly elected members 
that includes a Town Nazim (mayor) and a Naib Nazim (deputy mayor). 
(48) 
 
2.2 Study Area:- The retrospective study was conducted in four PDCs 
that are functioning as primary preventive centers for DM in their 
localities.  
 
2.3 Study Population:- general population, living in middle and low 
socio-economic urban areas of Karachi, mainly in the Gulberg, Gulshan, 




2.4 Research Design 
This study was conducted at selected PDCs which are run by one year 
diploma in Diabetology trained family physicians, known as Associate 
Diabetologists. These PDCs are affiliated with BIDE, an integral part of 
Baqai Medical University (BMC), Karachi, Pakistan.  
The design was a retrospective study, including 691 medical records of 
T2DM patients which were reviewed to know the status of their primary 
care at the various PDCs. The review included non pregnant diabetic 
patients 20 years of age and older with a definitive diagnosis of T2DM. 
These patients were seen on their first visit for primary diabetes care at 
four PDCs in four townships of Karachi district between 1 Jan 2005 to 29 
Dec 2006. The entire medical records were examined for evidence of 
documentation of testing and treatment. Variables from medical records 
included: 
Patient demographics (gender, age), height, weight, Body Mass Index 
(BMI), family history of DM, history of tobacco consumption, measures of 
glycemic control (fasting blood glucose, random blood glucose and 
glycosylated hemoglobin A1c -HbA1C), systolic blood pressure (SBP), 
diastolic blood pressure (DBP), lipid profile, urine detailed report especially 
for albumin, microalbuminuria, 24 hrs urinary protein, 24 hrs Creatinine 
clearance, serum Creatinine and documentation of or referral for dilated 
eye examination and lower limb assessment (pulses, reflexes, touch and 
vibrations). Diagnosis of and treatment of chronic comorbid conditions 
such as hypertension, dyslipidemia, nephropathy and cardiovascular 
disorder were also recorded. 
There was no patient contact or testing performed as part of this study. 
All information were collected as found in medical records at the four 
PDCs. Information had been recorded in the patient’s medical forms 
according to the PDCs usual practices.  
 
2.5 Sample Selection 
2.5.1 Criteria for Inclusion 
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All non-pregnant adults aged 20 years and older suffering from T2DM at 
the time of their registration at the PDCs for treatment. These patients 
were registered following a routine visit by T2DM outpatients at the PDCs 
between 1 Jan 2005 to 29 Dec 2006. 
 
2.5.2 Criteria for Exclusion 
Those pregnant, aged less than 20 years and suffering from type 1 DM 
were not included in the study.  
 
2.6 Selection Procedure 
The medical records of T2DM patients at the PDCs between 1 Jan 2005 to 
29 Dec 2006 that fulfilled the inclusion criteria were included in the study. 
During this period 691 medical records met the inclusion criteria and were 
reviewed and selected for inclusion in our study. 
 
2.7 Data Collection:  
All related variables found on the medical records were used to assess 
whether recommended ADA guidelines (2004) for T2DM management are 
being implemented by the trained FPs or not in this study.  
 
2.7.1 Variable definition 
In our study biochemical and clinical information from T2DM patients’ 
medical records were obtained from the following relevant variables:  
Demographic variables 
◘ Gender – physical appearance of sex (male or female) 
◘ Age – expressed in years 
Age was categorized into three groups as:  
20-40 years 
41-60 years and  
≥61 years old 
The duration of diabetes grouped as:   
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Duration of Diabetes: 
1 = < 2 years  
2 = 2 – 10 years 
3 = >10 years 
 
Clinical variables 
◘ Tobacco Consumption 
◘ Family history of DM 
◘ Weight – expressed in Kilograms and measured by using portable 
weight machine. 
◘ Height – expressed in centimeters and measured with the subject 
standing barefoot with both heels together erect against a wall having 
markings in centimeters. 
◘ Body Mass Index (BMI) 
BMI was calculated according to the formula BMI = weight/height2 
(kg/m²). Obesity taken as BMI > 25 kg/m2 as suggested by the Asian cut 
off levels.  
Indian Asians generally have high upper-body adiposity, causing higher 
insulin resistance, despite having a lean BMI. In February 2000, the WHO 
Regional Office for the Western Pacific, the International Association for 
the Study of Obesity, and the International Obesity Task published 
provisional recommendations for adults in Asia-Pacific as overweight at 
BMI >23kg/m2 and obesity at BMI >25kg/m2 (49). 
According to the new recommendations the Asian cut off values for BMI 
used: 
 
BMI: (kg/m2)    
Underweight = 1 (<18.5 kg/m2) 
Normal = 2 (18.5 – 22.9 kg/m2) 
Overweight = 3 (23 – 25 kg/m2) 
Obese = 4 = (>25 kg/m2) 
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◘ Blood pressure (BP) 
Hypertension (HTN) defined as either BP >140/90 mmHg or isolated SBP 
and DBP of >140 and 90 mmHg respectively and measured by mercury 
sphygmomanometers. 
Diagnosis of Hypertension: In our patients, diagnosis of hypertension 
was recorded if patient was documented with BP >140/90 mmHg or on 
antihypertensive treatment. 
Blood pressure control taken as: 
 
SBP: (mm Hg) 
≤130 mm Hg = Normal 
>130 mm Hg = Sys. Hypertension 
 
DBP: (mm Hg) 
≤80 mm Hg = Normal  
>80 mm Hg = Dias. Hypertension  
 
HTN:  
≤130/80 mmHg = Normal  
>140/90 mmHg = Hypertensive  
 
◘ Fundoscopy 
The fundus examined using Vista 20 direct ophthalmoscope by a 
diabetologist. Retinopathy classified as normal background (presence of 
microdots and hard exudates), pre-proliferative and proliferative 
(presence of soft exudates and new vessels) or maculopathy.  
 
◘ Foot Examination 
Peripheral neuropathy defined as absent touch or vibratory sensations of 
the feet. Touch sensation assessed by 10gm monofilament and vibration 
sensation by 128 Hz frequency tuning fork. A standardized filament called 
monofilament is pressed against part of the foot. When the filament 
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bends, its tip is exerting a pressure of 10 grams. (50) Subjects with 
absent dorsalis pedis or posterior tibial pulses on examination with or 
without a history of intermittent claudication labeled as having peripheral 
vascular insufficiency (PVI).  
◘ Aspirin 
◘ Statin 
◘ ACE Inhibitors 
◘ Anti Hypertensive 
◘ Insulin 
 
Laboratory variables  
◘ Fasting Blood Glucose (FBG) 
   FBG estimated by glucose oxidase method. 
◘ Random Blood Glucose (RBG) 
◘ HbA1c  
Good glycemic control was defined as HbA1c <7%. Glycemic control 
assessed by measuring HbA1c by DiaSTAT Hemoglobin A1c Analyzer, Bio-
Rad. HbA1c further grouped as: 
≤7   (Good) 
>7 & ≤8  (Fair) 
>8 & ≤9  (Poor) 
>9   (Bad) 
◘ Serum Creatinine 
◘ Proteinuria  
Nephropathy defined as protein > 1+ on dipstick (Combur 10, Roche 
Diagnostics) with no other abnormal findings on urinary examination.  
◘ Microalbuminuria 
◘ 24 hrs Proteinuria 
◘ 24 hrs Creatinine Clearance  
◘ Lipid Profile – TGs, TC, LDL and HDL 
Enzymatic methods (GPO-PAP and CHOD-PAP, Roche Diagnostics) used 
for lipid profile tests. 
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Total cholesterol-to-HDL ratio (TC/HDL Ratio) 
The usual method of calculating the risk of atherosclerosis is calculating 
the ratio of total cholesterol to HDL cholesterol which can be obtained by 
dividing total cholesterol by HDL cholesterol.  
Reports from the Framingham Heart Study suggest that for men, a total 
cholesterol-to-HDL ratio of 5 signifies that they're at average risk for heart 
disease; 3.4, about half the average; and 9.6, about double the average. 
Women tend to have higher HDL levels, so for them, a ratio of 4.4 
signifies average risk; 3.3 is about half the average; and 7, about double.  
Other risk factors to be considered for assessing heart disease risk and 
determining steps that should be taken to reduce it include body weight, 







Males >40 mg/dl 






2.7 Data handling 
The data was entered into Microsoft Excel 2002 and this raw data was 
checked in Karachi, Pakistan. After arriving in Oslo, Norway, the raw data 
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in Excel was converted to SPSS 16.0 for Windows software for data 
analysis. 
 
2.8 Statistical Analysis 
The data was analyzed on SPSS version 16.0. Demographic results for 
age, sex, duration of T2DM, medication used, and presence of other 
diagnosis were descriptive. Frequencies, cross-tabs (Chi-square test) and 
measures of central tendency were used to compare medical record 
information with ADA standards.   
In order to assess association of chronic complications with age and 
duration of diabetes, subjects were categorized into two age groups and 
two groups for duration of diabetes. Frequency of chronic complications in 
relatively younger and older subjects and in subjects with shorter and 
longer duration of diabetes was calculated. We used Chi-square test to 
assess the statistical significance of these differences. Statistical 
significance set at p < 0.05.  
 
2.9 Ethical issues 
The medical records of the selected patients evaluated without any breach 
of confidentiality regarding their identification code. Approval was sought 
and given by the Ethical Committee in Norway and the study carried out 


















































3.1 Findings of the Study 
The medical records of 691 T2DM patients including 332 men and 359 
women visiting four different PDCs for their first visits were audited to 
learn the implementation of ADA recommended guidelines.  
 
3.1.1 Individual PDCs: 
These patients came to four different PDCs that were located in different 
townships of Karachi.  
 
3.1.1.1 PDC1 - was located in Gulshan Township where 248 patients 
(131 men and 117 women) came during the study period. In PDC1, the 
screening rates and metabolic outcomes in the patients with type 2 
diabetes for different measures was better than the other three PDCs. The 
screening rates were good for almost all measures, especially for lipid 
profiles, microalbuminuria, dilated eye examination and lower leg 
examination. Patients were comparatively better screened for diabetes 
management and chronic complications at this PDC.  
The mean age of patients was 53 ± 10 years; averaged duration of 
diabetes was 7 years, mean weight 69.7 ± 12.6 kg; mean BMI 27 kg/m2 
and mean BP was 142/88 mmHg. Mean FBG 181 ± 62.7 mg/dl; mean 
HbA1c 8.96 ±1.2%; mean TGs 249.6 ± 101.2 mg/dl; mean TCs 194 ± 
37.6 mg/dl; mean HDL 38 ± 5.9 mg/dl and mean LDL 116 ± 26.6 mg/dl. 
Retinopathy seen in 32.6%; nephropathy in 15.03%; hypertension in 
64.3%; dyslipidemia in 91.4%; CVD in 7.7%; peripheral neuropathy in 
20% and peripheral vascular insufficiency (PVI) in 15%. 
 
3.1.1.2 PDC2 – located in Gulberg Township, 205 patients (87men and 
118 women) came for visit. The screening rates were good for HbA1c and 
diabetes complications. The mean age of patients was 51.41 ± 11 years; 
averaged duration of diabetes was 6.5 years; mean weight 69 ± 13.5 kg; 
mean BMI 25.8 kg/m2 and mean BP was 137/86 mmHg. Mean FBG 182.17 
± 60 mg/dl; mean HbA1c 8.9 ±1.6%; mean TGs 203.8 ± 145 mg/dl; 
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mean TCs 193.4 ± 52.2 mg/dl; mean HDL 39.7 ± 4.8 mg/dl and mean 
LDL 111.14 ± 34.6 mg/dl. Retinopathy seen in 26.3%; nephropathy in 
60%; hypertension in 61.3%; dyslipidemia in 74%; CVD in 3.4%; stroke 
in 0.5%; peripheral neuropathy in 16.3% and PVI in 13.8%. 
 
Table 1 (a): Show the number of patients who were or were not 
screened for tests and examinations in PDC 1 and PDC 2 
 


































N            % 










N          % 
Age 247        99.6 1           0.4 -        - 197          96.1 8                 3.9 -           - 
Duration of DM 240        96.8 8           3.2 -        - 188          91.7 17               8.3 -           - 
Family history of DM 248      100.0 -                - -        - 204          99.5 1                 0.5 -           - 
Tobacco consumption 248      100.0 -                - -        - 195          95.1 10               4.9 -           - 
Weight 247        99.6 1           0.4      -        - 174          84.9  31              15.1      -           - 
Height 247        99.6 1           0.4      -        - 147          71.7 58               28.3      -           - 
BMI 247        99.6 1          0.4 -        - 146          71.2 59               28.8 -           - 
BP 238        96.0 10        4.0 -        - 119          58.0 86               42.0 -           - 
FBG 144        58.1 104     41.9 -        - 92            44.9 113             55.1 -           - 
RBG 216        87.1  32      12.9 -        - 108          52.7  97              47.3 -           - 
HbA1c 162        65.3 86       34.7 -        - 46            22.4 152             74.1 7        3.4 
TGs 145        58.5 103     41.5 -        - 36            17.6  168            82.0 1        0.5 
TCs 149        60.1 99       39.9 -        - 45            22.0 159             77.6 1        0.5 
HDL 143        57.7 105     42.3 -        - 36            17.6  168            82.0 1        0.5 
LDL 143        57.7 105     42.3 -        - 36            17.6  168            82.0 1        0.5 
S. Creatinine 165        66.5 82       33.1 1       0.4 61            29.8 138             67.3 6        2.9 
Urine analysis 15          6.0 232     93.5 1       0.4 46            22.4 155             75.6 4        2.0 
Microalbuminuria 126        50.8 122     49.2 -          - 40            19.5 165             80.5 -          - 
24 hrs urinary protein 8            3.2 239     96.4 1       0.4 2              1.0 203             99.0  
24 hrs creatinine clear. 4            1.6 244     98.4 -        - 1              0.5 204             99.5 -          - 
Fundoscopy 145        58.5 103     41.5  -        - 26            12.7 179             87.3  -          - 
Foot examination: For 
Foot Ulcer 
248      100.0 
(7) 
-            - -         - 205        100.0 
(0) 
-                   - -          - 
For pulses: Popliteal 230         92.7 18         7.3 -        - 87            42.4 118             57.6 -          - 
Post. tibialis 230         92.7 18         7.3 -        - 94            45.9 111             54.1 -          - 
Dorsalis pedis 230         92.7 18         7.3 -        - 94            45.9 111             54.1 -          - 
For vibrations 210         84.7 38       15.3 -        - 85            41.5 120             58.5 -          - 
For touch sensation 210         84.7 38       15.3 -        - 86            42.0 119             58.0 -          - 
For reflexes: (Knee) 
(Ankle) 
210         84.7 
210         84.7 
38       15.3      
38       15.3 
-        - 
-        - 
83            41.5 
86            42.0 
122             59.5      
119             58.0 
-          - 
-          - 
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Table 1 (b): Show the number of patients who were or were not 
screened for tests and examinations in PDC 3 and PDC 4 
 






















N            % 




























N      % 
Age 142        98.6 2                   1.4 -        - 93           98.9 1           0.1 -        - 
Duration of DM 142        98.6 2                   1.4 -        - 94         100.0 -                - -        - 
Family history of DM 135        93.8 9                   6.2 -        - 93           98.9 1           0.1 -        - 
Tobacco consumption 144      100.0 -                   - -        - 84           89.4 10        10.6 -        - 
Weight 131        91.0 13                 9.0      -        - 69           73.4        25        26.6                   - - 
Height 127        88.2 17               11.8      -        - 66           70.2 28        29.8 -        - 
BMI 127        88.2 17               11.8 -        - 65           69.1 29        30.9 -        - 
BP 143        99.3 1                  0.7 -        - 93           98.9 1          0.1 -        - 
FBG 74          51.4 70               48.6 -        - 58           61.7 36        38.3 -        - 
RBG 125        86.8 19               13.2 -        - 86           91.5 8          8.5 -        - 
HbA1c 46          31.9 92               63.9 6        4.2 54           57.4 40        42.6 -        - 
TGs 64          44.4 75               52.1 5        3.5 52           55.3 33        35.1 9        9.6 
TCs 70          48.6 69               47.9 5        3.5 56           59.6 38        40.4 -        - 
HDL 62          43.0 77               53.5           5        3.5 50           53.2 35        37.2 9        9.6 
LDL 66          45.8 73               50.7 5        3.5 50           53.2 35        37.2 9        9.6 
S. Creatinine 96          66.7 41               28.5 7        4.9 65           69.1 19        20.2 10    10.6 
Urine analysis 79          54.8 59               41.0 6        4.2 52           55.3 31        33.0 11    11.7 
Microalbuminuria 3            0.7 141             99.3 -          - 3             3.2 91        96.8 -          - 
24 hrs urinary protein 2            1.4 141             97.9 1        0.7 6             6.4 87        92.6 1       1.1 
24 hrs creatinine clear. 1            0.8 142             98.4 1        0.8 5             5.3 88        93.6 1       1.1 
Fundoscopy 16          11.1 125             86.8 3        2.1 24           25.5 69        73.4  1       1.1 
Foot examination: For 
Foot Ulcer 
144      100.0 
(4) 
-                   - -         - 94         100.0 
(3) 
-              - -         - 
For pulses: Popliteal  -                - 144            100.0 -        - 1              1.1 93        98.9 -        - 
Post. tibialis  -                - 144            100.0 -        - 1              1.1 93        98.9 -        - 
Dorsalis pedis  -                - 144            100.0 -        - 1              1.1 93        98.9 -        - 
For vibrations  -                - 144            100.0 -        - 1              1.1 93        98.9 -        - 
For touch sensation  -                - 144            100.0 -        - 1              1.1 93        98.9 -        - 
For reflexes: (Knee) 
(Ankle) 
 -                - 
 -                - 
144            100.0 
144            100.0 
-        - 
-        - 
1              1.1 
1              1.1 
93        98.9 
93        98.9 
-        - 
-        - 
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Table 2 (a): Show the number of patients screened or not screened for 
diabetes management and complications at PDC1 and PDC2 
 
PDC1 (N=248)                                                            PDC2 (N=205) 
 
 
3.1.1.3 PDC3 - located in Orangi Township, 144 patients (68 men and 76 
women) visited it. The screening rates were good for BP and diabetes 
management. Patients were not screened for peripheral vascular 
insufficiency. 
The mean age of patients was 48 ± 9.5 years; averaged duration of 
diabetes was more than 2 years, mean weight 64.3 ± 12.2 kg; mean BMI 
26 kg/m2 and mean BP was 135/84 mmHg. Mean FBG 224.5 ± 79 mg/dl; 
mean HbA1c 9.4 ±2.1%; mean TGs 186 ± 109 mg/dl; mean TCs 201.2 ± 
47 mg/dl; mean HDL 41.45 ± 9.6 mg/dl and mean LDL 125.3 ± 37.3 
mg/dl. Retinopathy seen in 40%; nephropathy in 71.4%; hypertension in 









N             % 
Not screened / 
Missing 
 




N             % 
Not screened / 
Missing 
 
N                  % 
Management:  
Aspirin 248        100     -             - 205        100    -                  - 
ACE 240        96.8 8                 3.2 140         68.3 65              31.7       
Anti HTN 238        96 10               4 119         58 86              42 
Statin 151        60.9 97              39.1 48           23.4 157            76.6 
Insulin 248        100     -             - 204         99.5    -                  - 
Complications:  
Retinopathy 147        59.3 101             40.7 38           18.5 167            81.5 
Nephropathy 133        53.6 115             46.4 195         95.1 10              4.9 
Hypertension 248        100     -             - 119         58 86              42 
Hyperlipidemia 248        100     -             -  46          22.4       159            77.6 
CVD 207        83.5 41              16.5 205         100     -             - 
Stroke 216        87.1 32              12.9 205         100     -             - 
Peripheral Neuropathy 169        68.1 79               31.9 49           23.9 156            76.1 
Peripheral Vascular 
Insufficiency 
229        92.3 19               7.7 87           42.4 118            57.6 
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Table 2 (b): Show the number of patients screened or not screened for 
diabetes management and complications at PDC3 and PDC4 
  






















N              % 
Not screened / 
Missing 
 




N             % 
Not screened / 
Missing 
 
N                   % 
Management:  
Aspirin 144        100     -             - 94          100     -             - 
ACE 143        99.3 1                 0.7 93          98.9 1                 1.1 
Anti HTN 143        99.3 1                 0.7 93          98.9 1                 1.1 
Statin 74          51.4 70               48.6 59          62.8 35               37.2 
Insulin 248        100     -             - 94          100     -             - 
Complications:  
Retinopathy 15          10.4 129             89.6 24          25.5 70               74.5 
Nephropathy 7            4.9 137             95.1 9            9.6 85               90.4 
Hypertension 143        99.3 1                 0.7 93          98.9 1                 1.1 
Hyperlipidemia 71          49.3  73              50.7 58          61.7  36              38.3  
CVD 111        77.1 33               22.9 84          89.4 10              10.6             
Stroke 109        75.7 35               24.3 94          100     -             - 
Peripheral Neuropathy 64          44.4 80               55.6 41          43.6 53               56.4 
Peripheral Vascular 
Insufficiency 
-               - 144             100 1            1.1 93               98.9 
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Table 3 (a): Means of anthropometric and biochemical parameters of 
































Mini. Maxi. Mean 2 Std 
Dev. 
± 
Age 247 30.0 84.0 52.5 9.9 197 20.0 80.0 51.4 10.9 
Weight 247 41.0 117.0 69.7 12.6 174 43.0 132.0 68.9 13.5 
Height 247 142.0 187.0 160.8 8.9 147 141.0 184.0 163.6 9.7 
BMI 247 17.0 48.9 26.9 4.3 146 15.2 44.3 25.8 4.7 
DBP 238 60.0 120.0 87.7 11.1 119 70.0 120.0 85.5 8.1 
SBP 238 80.0 210.0 142.0 23.1 119 100.0 200.0 137.3 17.6 
FBG 144 60.0 390.0 181.5 62.7 92 76.0 379.0 182.1 59.5 
RBG 216 78.0 900.0 283.1 106.6 108 86.0 474.0 264.5 84.8 
HbA1c 162 5.7 13.1 8.9 1.2 46 6.0 12.8 8.9 1.6 
TGs 145 62.0 700.0 249.6 101.2 36 44.0 758.0 203.8 145.4 
TCs 149 90.0 345.0 194.1 37.6 45 128.0 410.0 193.4 52.2 
HDL 143 24.0 67.0 37.9 5.8 36 32.0 57.0 39.7 4.8 
LDL 143 58.0 243.0 115.98 26.6 36 60.0 205.0 111.1 34.6 
S. Creatinine 165 .6 9.0 1.1 .6 61 .5 1.5 .9 .2 
Microalbuminuria 122 50.0 535.0 150.7 102.7 4 32.0 116.0 87.0 37.4 
24 hrs U. protein 8 90.0 190.0 123.7 33.7 2 435.0 850.0 642.5 293.4 
24 hrs Creat. 
Clear. 
4 50.0 109.0 71.0 26.1 1 354.0 354.0 354.0 . 
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Table 3 (b): Means of anthropometric and biochemical parameters of 










Mini. Maxi. Mean 2 Std 
Dev. 
± 
Age 142 23.0 72.0 47.9 9.5 93 26.0 86.0 50.1 10.6 
Weight 131 40.0 107.0 64.3 12.2 69 41.5 123.0 73.2 16.6 
Height 127 136.0 188.0 157.4 9.3 66 138.0 183.0 159.1 10.3 
BMI 127 14.1 46.3 26.1 4.5 65 17.5 45.9 28.8 5.8 
DBP 143 60.0 120.0 83.5 8.1 93 60.0 100.0 83.2 8.0 
SBP 143 90.0 200.0 134.6 17.3 93 110.0 190.0 134.1 15.0 
FBG 74 75.0 416.0 224.5 79.1 58 80.0 408.0 206.7 80.8 
RBG 125 92.0 593.0 287.2 103.8 86 76.0 557.0 274.2 98.9 
HbA1c 46 5.0 13.8 9.4 2.1 54 5.8 13.8 9.5 2.0 
TGs 64 36.0 558.0 186.9 109.0 52 73.0 743.0 212.1 137.1 
TCs 70 95.0 344.0 201.1 46.9 56 106.0 376.0 185.9 41.9 
HDL 62 24.0 93.0 41.4 9.6 50 23.0 61.0 39.2 7.3 
LDL 66 48.0 205.0 125.3 37.3 50 51.0 248.0 116.8 30.6 
S. Creatinine 96 .5 2.0 .91 .2 65 .6 2.7 1.0 .3 
Microalbuminuria 2 20.0 100.0 60.0 56.5 2 100.0 173.0 136.5 51.6 
24 hrs U. protein 2 216.0 270.0 243.0 38.1 6 120.0 672.0 287.3 201.6 
24 hrs Creat. 
Clear. 1 73.0 73.0 73.0 . 5 71.0 98.0 84.9 11.2 
 
Table 4: shows patients within different PDCs with parameters for good 
diabetes control 
                               
Variables 
(Mean Values) 




PDC2 Mean 2 Std 
Dev. 
± 








Age (years) √ 52.6 9.9 - - - - - - - - - 
BMI (kg/m
2
) - - - √ 25.8 4.7 - - - - - - 
BP (mm Hg) - - - - - - - - - √ 134/83 - 
FBG (mg/dl) √ 181.5 62.7 - - - - - - - - - 
RBG (mg/dl) - - - √ 264.5 84.8 - - - - - - 
HbA1c (%) - - - √ 8.9 1.6 - - - - - - 
TGs (mg/dl) - - - - - - √ 186.9 109 - - - 
TCs (mg/dl) - - - - - - - - - √ 185.9 41.9 
HDL (mg/dl) - - - - - - √ 41.5 9.6 - - - 
LDL (mg/dl) - - - √ 111.14 34.6 - - - - - - 
S. Creatinine 
(mg/dl) - - - - - - √ 0.9 0.26 - - - 
Microalbuminuria 
(mg/dl) - - - - - - √ 60 56.5 - - - 
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Table 5: Shows patients within different individual PDCs with parameters 




PDC1 Mean 2 Std 
Dev. 
± 




PDC3 Mean 2 Std 
Dev. 
± 




Age (years) - - - - - - √ 48 9.5 - - - 
BMI (kg/m
2
) - - - - - - - - - √ 28.8 5.8 
BP (mm Hg) √ 142/88 - - - - - - - - - - 
FBG (mg/dl) - - - - - - √ 224.5 79.1 - - - 
RBG (mg/dl) - - - - - - √ 287.2 103.9 - - - 
HbA1c (%) - - - - - - - - - √ 9.5 2 
TGs (mg/dl) √ 249.6 101.2 - - - - - - - - - 
TCs (mg/dl) - - - - - - √ 201.1 46.9 - - - 
HDL (mg/dl) √ 38 5.8 - - - - - - - - - 
LDL (mg/dl) - - - - - - √ 125.3 37.3 - - - 
S. Creatinine 
(mg/dl) √ 1.1 0.6 - - - - - - - - - 
Microalbuminuria 
(mg/dl) - - - - - - - - - √ 136.5 51.6 
 
 
3.1.1.4 PDC4 – located in Liaquatabad Township was visited by 94 
patients (46 men and 48 women) during the study period. The screening 
rates were good for serum creatinine and diabetes management. Only one 
patient was screened for peripheral vascular insufficiency. 
The mean age of patients was 50 ± 10.6 years; averaged duration of 
diabetes was 2 years, mean weight 73.3 ± 16.6 kg; mean BMI 28.8 kg/m2 
and mean BP was 134/83 mmHg. Mean FBG 206 ± 81 mg/dl; mean 
HbA1c 9.6 ± 2%; mean TGs 212.12 ± 137.2 mg/dl; mean TCs 186 ± 42 
mg/dl; mean HDL 39.2 ± 7.3 mg/dl and mean LDL 116.8 ± 30.6 mg/dl. 
Retinopathy was seen in 25%; nephropathy in 56%; hypertension in 
58%; dyslipidemia in 76% and CVD in 10.7%. 
 







Table 6: Shows patients within different individual PDCs with good (G) 




















Age (years) (G)*  - 99.6 (P)* - 96.1 - - - - - - 
Weight (kg) (G) - 99.6 - - - - - - (P) - 73.4 
Height (cm) (G) - 99.6 - - - - - - (P) - 70.2 
BMI (kg/m
2
) (G) - 99.6 (P) - 59.0 - - - - - - 
BP (mm Hg) - - - (P) - 58.0 (G) - 99.3 - - - 
HbA1c (%) - - - (G) - 74.1 (P) - 31.9 - - - 
Lipid Profile 
mg/dl (G) - 58.5 (P) - 18.7 - - - - - - 
S. Creatinine 
(mg/dl) - - - (P) - 29.8 - - - (G) - 69.1 
Urine Detailed 
Report (DR) (P) - 6.0 - - - - - - (G) - 55.3 
Microalbuminu
ria (mg/dl) (G) - 50.8 - - - (P) - 0.7 - - - 
Fundoscopy (G) - 58.5 - - - (P) - 11.1 - - - 
Lower Leg (LL) 
examination (G) - 88.1 - - - (P) - 0 (P) - 0 
Aspirin (G) - 100.0 (G) - 100.0 (G) - 100.0 (G) - 100.0 
ACE inhibitors - - - (P) -  68.3 (G) - 99.3 - - - 
Anti 
Hypertensive - - - (P) - 58.0 (G) - 99.3 - - - 
Statin - - - - - - - - - (G) - 62.8 
Insulin (G) - - (G) - - (G) - - (G) - - 
(G)* = Good; (P)* = Poor 
 


























Retinopathy (G) - 59.3 - - - (P) - 10.4 - - - 
Nephropathy - - - (G) - 95.1 (P) - 4.9 - - - 
Hypertension (G) - 100.0 (P) - 58.0 - - - - - - 
Hyperlipidemia (G) - 100.0 (P) - 22.4 - - - - - - 
CVD - - - (G) - 100.0 (P) - 77.1 - - - 
Stroke - - - (G) - 100.0 (P) - 75.7 (G) - 100.0 
Peripheral 




(G) - 92.3 - - - (P) - 0 (P) - 0 
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Tables 8 and 9: Show the number of T2DM patients who were or were 


















N      % 
Age 679        98.3 12               1.7 -        - 
Duration of DM 665        96.0 26               3.9 -        - 
Family history of DM 680        98.4 11               1.6 -        - 
Tobacco consumption 671        97.1 20               2.9 -        - 
Weight 621        90.0 70               10 -        - 
Height 587        85.0 104             15 -        - 
BMI 585        84.7 106             15.3 -        - 
BP 593        86.0 98               14 -        - 
FBG 368        53.3 323             46.7 -        - 
RBG 535        77.4 156             22.6 -        - 
HbA1c 308        44.6 353             51.1 30     4.3   
TGs 297        43.0 379             54.8 15     2.2 
TCs 319        46.2 358             51.8 14     2.0 
HDL 291        42.1 385             55.7 15     2.2 
LDL 295        42.7 381             55.1 15     2.2 
S. Creatinine 387        56.0 280             40.5 24     3.5 
Urine analysis 192        27.8 477             69 22     3.2 
Microalbuminuria 172        25.0 519             75 -          - 
24 hrs urinary protein 18            2.6 670             97 3       0.4 
24 hrs creatinine clear. 11            1.6 678             98.1 2       0.3 
Fundoscopy 211        30.5 476             69 4       0.5 
Foot examination: For 
Foot Ulcer 
691      100.0 
(14) 
-                   - -         - 
For pulses: Popliteal 317        46.0 374             54.0 -        - 
Post. tibialis 325        47.0 366             53.0 -        - 
Dorsalis pedis 325        47.0 366             53.0 -        - 
For vibrations 296        42.8 395             57.2 -        - 
For touch sensation 297        43.0 394             57.0 -        - 
For reflexes: (Knee) 
(Ankle) 
294        42.5 
297        43.0 
397             57.5      
394             57.0 
-        - 
























N      % 
Management:  
Aspirin 691        100 -                   - -         - 
ACE 616        89.1 75             10.9 -         - 
Anti HTN 593        86.0 98             14.0 -         - 
Statin 332        48.0 359           52.0 -         - 
Insulin 691        100.0 -                   - -         - 
Complications:  
Retinopathy 224        32.4 467           67.6 -         - 
Nephropathy 159        23.0 532           77.0 -         - 
Hypertension 593        86.0 98             14.0 -         - 
Hyperlipidemia 326        47.2 365           52.8 -         - 
CVD 607        87.8 84             12.2 -         - 
Stroke 624        90.3 67               9.7 -         - 




317        45.9 
 
374           54.1 
 
-         - 
 
 


















N      % 
Age 679           98.3 -                   - -        - 
20-40 years -                   - 125        18.4 -        - 
41-60 years -                   - 449        66.1 -        - 
≥61 years -                   - 105        15.5 -        - 
Duration of DM 665            96.0 -                   - -        - 
<2 years -                   - 167         25.1  -        - 
2-10 years -                   - 342         51.4 -        - 
>10 years -                   - 156         23.5 -        - 
Family history of DM 680            98.4 -                   - -        - 
Yes -                   - 407         59.0  
Tobacco consumption 671           97.1 -                   - -        - 
Non-smokers -                   - 593        88.4    -        - 
Ex-smokers -                   - 17            2.5 -        - 
Smokers -                   - 34            5.1 -        - 
Tobacco chewing -                   - 27            4.0 -        - 
BMI 585            84.7 -                   - -        - 
<25 kg/m2 -                   - 108         18.5 -        - 


















N      % 
BP 593            86.0 -                   - -        - 
≤130/80 mmHg -                   - 265         44.7 -        - 
>130/80 mmHg -                   - 328         55.3 -        - 
FBG 368            53.3 -                   - -        - 
<130 mg/dl -                   - 60           16.3 -        - 
>130 mg/dl -                   - 308         83.7 -        - 
RBG 535            77.4 -                   - -        - 
≤200 mg/dl -                   - 114         21.3 -        - 
>200 mg/dl -                   - 421         78.7 -        - 
HbA1c 308            44.6 -                   - 30     4.3   
<7 % -                   - 31         10.06 -        - 
>7 % -                   - 277        90.0 -        - 
TGs 297            43.0 -                   - 15     2.2 
≤150 mg/dl -                   - 89          30.0 -        - 
>150 mg/dl -                   - 208        70.0 -        - 
TCs 319            46.2 -                   - 14     2.0 
≤200 mg/dl -                   - 190         59.6 -        - 
>200 mg/dl -                   - 129         40.4 -        - 
HDL 291            42.1 -                   - 15     2.2 
<40 mg/dl  -                   - 142         48.8 -        - 
≥40 mg/dl -                   - 139         47.8 -        - 
≥50 -                   - 10            3.4 -        - 
LDL 295            42.7 -                   - 15     2.2 
≤100 mg/dl -                   - 94           39.1 -        - 
>100 mg/dl -                   - 201         68.9 -        - 
S. Creatinine 387            56.0 -                   - 24     3.5 
≤1.2 mg/dl -                   - 337         87.1 -        - 
>1.2 mg7dl -                   - 50           12.9 -        - 
Urine analysis 192            27.8 -                   - 22     3.2 
Normal -                   - 83           43.2 -        - 
Abnormal -                   - 109         56.8  -        - 
Microalbuminuria 172            25.0 -                   - -          - 
Yes -                   - 129         75.0 -        - 
Negative -                   - 43           25.0 -        - 
Fundoscopy 211            30.5 -                   - 4       0.5 
Pathologic changes -                   - 67           31.8 -        - 
Foot examination: For 
Foot Ulcer 
 
691          100.0 
 
14            2.0 
 








Table 11: Cut off values for biochemical variables according to ADA 
guidelines 
 




Mean 2 Std. 
Dev. 
Fasting Blood Glucose (FBG) (mg/dl) 368 - 194.32 70.5 
<130 mg/dl 60 16.3 - - 
≤ 200 mg/dl 166 45.1 - - 
>200 mg/dl 142 38.6 - - 
HbA1c 308 - 9.13 1.6 
≤ 7 31 10.1 - - 
>7 277 89.9 - - 
Cholesterol (mg/dl) 319 - 194.15 42.7 
≤200 190 59.6 - - 
>200 129 40.4 - - 
Triglycerides (mg/dl) 297 - 224.00 118.1 
≤150 89 30.0 - - 
>150 208 70.0 - - 
Low Density Lipoprotein (LDL) (mg/dl) 295 - 117.62 31.1 
≤100 94 31.9 - - 
>100 201 68.1 - - 
High Density Lipoprotein (HDL) (mg/dl) 291 - 39.16 7.1 
Male 141 48.5 38.41 7.5 
<40 (Low HDL) 78 55.3 - - 
≥40 60 42.6 - - 
≥50 3  2.1 - - 
Female 150 51.5 39.86 6.5 
<40 (Low HDL) 64 42.7 - - 
≥40 79 52.7 - - 




Age of 679 (325 men and 354 women) patients was documented, we 
further grouped them and found that 18.4% were between 20- 40 years 
of age; 66.1% were between 41-60 years of age and 15.5% were in ≥61 
years of age. This indicates that 66.1% patients represent a majority 
having diabetes aged between 41-60 years. This also reflects that 







Table 12: Means of anthropometric and biochemical parameters of T2DM 




Mini. Maxi. Mean 2 Standard 
Deviation 
± 
Age 679 20.0 86.0 50.9 10.4 
Weight 621 40.0 132.0 68.8 13.5 
Height 587 136.0 188.0 160.6 9.6 
BMI 585 14.0 49.0 26.7 4.7 
DBP 593 60.0 120.0 85.5 9.6 
SBP 593 80.0 210.0 138.1 19.8 
FBG 368 60.0 416.0 194.3 70.5 
RBG 535 76.0 900.0 278.8 100.7 
HbA1c 308 5.0 13.8 9.1 1.6 
TGs 297 36.0 758.0 224.0 118.1 
TCs 319 90.0 410.0 194.1 42.7 
HDL 291 23.0 93.0 39.1 7.1 
LDL 295 48.0 248.0 117.6 31.1 
S. Creatinine 387 .5 9.0 1.0 .4 
Microalbuminuria 130 20.0 535.0 147.1 101.0 
24 hrs U. protein 18 90.0 850.0 249.1 209.0 
24 hrs Creat. Clear. 11 50.0 354.0 103.2 84.9 
 
 
3.1.3 Duration of Diabetes: 
A total of 665 patients had given history of duration of diabetes and the 
average duration of diabetes was 8 years. And of these 51.7% patients 
had 2-10 years duration of diabetes and 100 patients were aged between 
41-60 years with >10 years duration of diabetes.  
 
Table 13: Frequency distribution of duration of DM according to gender 
inT2DM subjects  
Gender 
Duration of T2DM 






















Total 167 342 156 665 
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Table 14: Frequency distribution of duration of DM according to age 





Duration of T2DM 
 






52   
(43.7%) 























Total 165 336 154 655 
 
 





3.1.4 Family History of Diabetes: 
Of the 691 records reviewed, positive family history of diabetes was seen 
in 60% of the patients.  
 
 
Table 15: Frequency distribution of family history of DM according to age 
group in T2DM subjects 
Age Group 
 
Family History of T2DM 
No            Yes      Not Known  Total 
20-40 years 35 90 - 125 
41-60 years 176 265 8 449 
≥61 years 53 49 3 105 
Total 264 404 11 679 
Documented 679 (98.3%) Missing 12 (1.7%) 
 
Fig 2: Cluster bars between family history of DM and age group in T2DM 
at all PDCs 
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3.1.5 Tobacco Consumption: 
The records showed that 86% were nonsmokers. Seventeen patients were 
ex-smokers, 34 were smokers and 27 had the habit of chewing tobacco in 
pan. 





             Total  
  n=691      percentage 
Non smokers 593 85.8 
Smokers 34 4.9 
Tobacco chewing 27 3.9 
Ex smokers 17 2.5 
Not known/Missing 20 2.9 
Total 691 100 
 
 
3.1.6 Body Mass Index: 
A total of 585 patients had their BMI measured and of these 7 patients 
were underweight with a BMI of <18.5 kg/m2, 17.2%  had normal BMI of 
18.5 - 22.9 kg/m2, 21% were overweight and 60.5% were obese with a 
BMI of >25 kg/m2. Three hundred and fifty-four subjects in all PDCs were 
obese and of these 42.3% were in the age group 41 – 60 years. Of 293 
females who had their BMI measured, 67% were obese with a BMI 
>25kg/m2 and of 292 males 53.8% were obese. 
 
Table 17: Percentage distribution of BMI according to gender in T2DM 
subjects in all PDCs 
 















































<18.5   18.5-22.9    23-25       >25         





































Total 7 97 122 351 577 
Documented 577 and Missing 114 
 
The above table shows that 351 (60.8%) subjects in all PDCs were obese 
and of these 244 (69.5%) were in the age group 41 – 60 years. 
 
 
Fig 3: Cluster bars between BMI and age group in T2DM at all PDCs 
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3.1.7 Blood Pressure: 
The blood pressure of 593 patients was documented and of these 285 
were males and 308 females. Patients with type 2 diabetes had an 
average BP level of 138/86 mmHg. Of 593 patients, normal diastolic BP 
≤80 mm Hg was seen in 49% patients and high diastolic BP >80 mm Hg 
recorded in 51% patients. Normal systolic BP ≤130 mm Hg was seen in 
61.2% and high systolic BP >130 mm Hg in 38.8%. In 35.3% patients, 
diastolic BP ≥90 mm Hg was documented and 33.1% patients showed 
systolic BP ≥140 mm Hg. A total of 44.7% patients (140 men and 125 
women) had BP ≤130/80 mm Hg and 328 (55.3%) patients (145 men and 
183 women) had BP >130/80 of mm Hg. The data on blood pressure 
showed that high blood pressure (≥130/80 mm Hg) was more in women 
than men.  
 
 
Table 19: DBP and SBP recorded in different age groups of T2DM subjects 
in all PDCs 
 
Age Group Normal 
DBP 
≤80 mm Hg 
Hypertensive 
DBP 





























































Table 20: Percentage of hypertension recorded in different age groups of 
T2DM subjects 

































Fig 4: Cluster bars between hypertension and age group in T2DM at all 
PDCs 
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Table 21: Percentage distribution of normotensive and hypertensive BP 































3.1.8 Fasting Blood Glucose: 
A total of 368 patients had their FBG measured, of which 40 had FBG 
between 80-120 mg/dl and 325 had FBG levels >120 mg/dl. The fasting 
blood glucose level averaged 194.32 ± 70.59 in these patients.  
 






<80             80-120        >120       Total 
Male 1 
 
20 163 184 
Female 2 
 
20 162 184 
Total 3 
 
40 325 368 
 
 
3.1.9 Random Blood Glucose: 
A total of 535 had RBG measured and 114 had RBG levels ≤200 mg/dl. In 
these patients, random blood glucose level averaged 278.86 ± 100.76 






HbA1c was measured in 308 patients and HbA1c of ≤7 seen in 10.15% >7 
and ≤8 in 14.6%, and >8 in 75.3% patients. Thirty patients were referred 
for HbA1c tests. In these patients the HbA1c level averaged 9.1±1.6%. 
HbA1c levels of >9 was seen in 30.2% of patients on insulin.  
 




             Total  
  n=308     % 
≤7 (Good) 31 10.1 
>7 ≤8 (Fair) 45 14.6 
>8 ≤9 (Poor) 93 30.2 
>9 (Bad) 139 45.1 
Total 308 100 
Screened 308(44.5%) Missing 383 (55.5%) 
 
 





































3.1.11 Lipid Profiles: 
Lipid profile showed that 297 patients had their triglycerides checked and 
of these 147 were men and 150 were women. In 30% patients 
triglycerides was ≤150 mg/dl and in 70% triglycerides was >150 mg/dl. 
Total cholesterol was checked in 319 patients (156 men and 163 women). 
In 190 (59.5%) cholesterol level was ≤200 mg/dl and in 129 (40%) >200 
mg/dl was recorded. Total Cholesterol to HDL ratio (TC/HDL Ratio) (52) 
calculated in a total of 287 patients of which 140 were male. In these 
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male patients 11 had a ratio of <3.4 (very low risk), 12 had a ratio of 4.0 
(low risk), 48 had a ratio of 5.0 (average risk), 69 had a ratio of 9.5 
(moderate risk) and none had a ratio of >23 (high risk). TC/HDL Ratio 
calculated in 147 female and of these 11 had TC/HDL ratio >3.3 (very low 
risk), 15 had a ratio 3.8 (low risk), 30 had a ratio 4.5 (average risk), 89 
had a ratio of 7.0 (moderate risk) and 02 had a ratio of >11 (high risk). In 
a total of 291 patients the HDL levels was recorded and in men HDL level 
≤40 mg/dl found in 107 (36.7%) and >40 mg/dl in 34 (11.7%). In 
women, HDL level of ≤50 mg/dl recorded in 145 (49.8%) and >50 mg/dl 
in only 5 (1.7%). In 295 patients, 32% had LDL levels ≤100 mg/dl and 
LDL >100mg/dl found in 68% patients. Fourteen patients were referred 
for lipid tests. Overall undesirable lipid profiles were seen more in men as 
compared to women. Patients with type 2 diabetes had an average 
cholesterol level of 194 mg/dl (2.18 mmol/l), an average triglyceride level 
of 224 mg/dl (2.52 mmol/l), an average HDL cholesterol level of 39 mg/dl 
(1 mmol/l), and an average LDL cholesterol level of 117 mg/dl (3 mmol/l).  
 




Test not done 379  54.8 
Test done 297  43.0 
Advised 15    2.2 
Total  691 100.0 
Total cholesterol 
Test not done 357  51.7 
Test done 320  46.3 
Advised 14   2.0 
Total  691 100.0 
HDL 
Test not done 385  55.7 
Test done 291  42.1 
Advised 15   2.2 
Total  691 100.0 
LDL 
Test not done 381  55.1 
Test done 295  42.7 
Advised 15   2.2 
Total  691 100.0 
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Table 26: Percentage distribution of Lipid profile according to gender 
 
Gender TGs mg/dl 
≤150     >150      
   TC mg/dl 
≤200       >200 
HDL mg/dl 
M ≤40            >40 
F  ≤50            >50        
LDL mg/dl 
 
≤100      >100 
Male 35           112 
23.8%   76.2% 
89             67 
57.1%     42.9% 
107                34          
36.7%        11.7%   
40             100 
28.6%     71.4% 
Female 54            96 
36.0%   64.0% 
101             62 
62.0%      38.0% 
145                  5 
49.8%          1.7% 
54            101 
34.8%      65.2% 
Total 89           208 
30.0%   70.0% 
190           129 
59.6%     40.4% 
142              149 
48.8%        51.2% 
94             201 
31.9%     68.1% 
 
3.1.12 Serum Creatinine: 
Serum creatinine was checked in 387 patients and 87.1% showed ≤1.2 
mg/dl, 12.4% had 1.3 – 2 mg/dl and 0.52% had >2 mg/dl. Twenty four 
patients were referred for serum creatinine tests. 
 
3.1.13 Urine Analysis: 
Urine analysis was recorded in 192 patients and 22 were referred to have 
the test done. 
 
3.1.14 Microalbuminuria: (30-300 mg/day) 
Urine microalbumin screening was recorded in 172 and of these patients 
75% had microalbuminuria.  
 
3.1.15 Eye Examination: 
Fundoscopy as part of dilated eye examination was done on 211 patients. 
The results showed that 78 had cataract, 38 had background retinopathy, 
16 had pre-proliferative retinopathy, 2 had proliferative retinopathy and 
11 were documented having abnormal changes. Four patients were 












 Male                    Female 
Total 




144   
(67.0%) 
Abnormal 7    
(6.8%) 
4    
(3.6%) 












1    
(1.0%) 
1   
(0.9%) 




8    
(7.8%) 
8    
(7.1%) 
16   
(7.4%) 
Referred 1     
(1.0%) 
3    
(2.7%) 








Table 28: Percentage distribution of Fundoscopy according to age group 
in T2DM subjects 












































































3.1.16 Lower Leg Examination: 
Fourteen patients (10 men and 4 women) had diabetic foot ulcer. 
Interestingly, 13 of these foot ulcers seen on the right foot. A total of 317 
patients examined for popliteal pulses; 325 for posterior tibialis and 
dorsalis pedis. Sense of vibration recorded in 296 and touch sensation in 
297 patients. Knee jerk reflexes recorded in 294 and 297 were examined 
for ankle jerk reflexes.  
 
3.1.17 Diabetes Management: 
The management of patients with type 2 diabetes was complex and nearly 
all patients required pharmacological therapy. Of the 691 patients, 41% 
were on Aspirin; 20.3% on ACE inhibitors; 27% on anti-hypertensive; 
15.6% on statin and 22% on insulin which was injected twice a day. While 
17 patients were counseled for insulin therapy and 2 were advised to start 
it. Though 75 patients had LDL value of >130 mg/dl of these only 13 were 
prescribed statin. BP ≥140/90 mm Hg was seen in 19.7% patients and 
they were prescribed anti- hypertensive medicines. While 23% patients 
who also had BP ≥140/90 mm Hg but they were not prescribed any anti-
hypertensive medicine. Patients who were taking antihypertensive 
medications; of these, 10.6% had a BP level of ≤140/90 mm Hg, and only 
5% had a BP level of ≤130/80 mm Hg. A total of 15.6% patients were on 
lipid-lowering medications. In patients taking lipid-lowering medication, 
the total cholesterol level averaged 208.12 mg/dl (5.33 mmol/l) 
208.12mg/dl and the triglyceride level averaged 266.12 mg/dl (3 mmol/l). 
The HDL cholesterol level averaged 40.90 mg/dl (1.04 mmol/l) and the 
LDL cholesterol level averaged 128.07 mg/dl (3.28 mmol/l). In patients 
not taking lipid-lowering medications, the total cholesterol level averaged 
191.24 mg/dl (4.9 mmol/l) and the triglyceride level averaged 215.88 
mg/dl (2.42 mmol/l). The HDL cholesterol level averaged 38.86 mg/dl (1 










N                       % 
Found to be 
on/suffering 
from: 
N                 % 
Management:  
Aspirin  691                  100.0 283             41.0 
ACE  616                    89.1 125             20.3 
Anti HTN  593                    86.0 160             27.0 
Statin  332                    48.1 52               15.6 
Insulin  691                  100.0 152             22.0 
Complications:  
Retinopathy  224                    32.4 70               31.3 
Nephropathy  159                    23.0 36               22.6 
Hypertension  593                    86.0 349             59.0 
Hyperlipidemia  326                    47.2 276             84.7 
CVD  607                    87.8 39                 6.4 
Stroke  624                    90.3 01                 0.2 
Peripheral 
Neuropathy 




 317                   46.0 
 
46               14.5  
 
 
3.1.18 Diabetes Complications: 
Many patients with type 2 diabetes had complications from their diabetes 
as screened during their first visit to the PDCs. Dyslipidemia was seen in 
84.7%. Microvascular complications like retinopathy were seen in 31.3%, 
nephropathy in 22.6% and peripheral neuropathy in 18.6%. Diabetic foot 
ulcer was seen in 2% patients. Macrovascular complications like 
hypertension were seen in 59%, cardiovascular disease in 6.4% and 
stroke in 0.2% patients. Peripheral vascular insufficiency found in 14.5% 
patients. 
Among the genders our data shows that more men had diabetic foot ulcer, 
nephropathy, CVD, stroke, peripheral neuropathy and peripheral vascular 
insufficiency as compared to women. Retinopathy and hypertension as 
chronic complications were seen more in women. Dyslipidemia was found 
almost equally in both genders.  
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- 2  
(4.3) 
















14 (35.9) 15  
(32.6) 










*CVD = Cardiovascular disease 
**PVI = Peripheral vascular insufficiency 
 
Most of the diabetes complications were seen in patients between 41-60 
years of age. 
 
Table 31: Duration of diabetes and various diabetes complications in 
































































*CVD = Cardiovascular disease 
**PVI = Peripheral vascular insufficiency 
 
Patients who had between 2-10 years duration of diabetes the chronic 
complications were higher in them. Those patients with >10 years of 
diabetes in them CVD, retinopathy and nephropathy were prominent. 
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*CVD = Cardiovascular disease 
**PVI = Peripheral vascular insufficiency 
 
Those with HbA1c ≤ 7%, 3 had retinopathy, 3 had nephropathy, 4 had 
peripheral neuropathy, 3 had CVD and 2 had PVI.  
HbA1c >9% seen in 29 with retinopathy, 16 with nephropathy, 17 with 
peripheral neuropathy, 10 with CVD and 16 with PVI. This shows that 
most patients suffering from diabetes complications had poor glycemic 
control. 
 
Table 33 (a): Percentage distribution Systolic BP, diastolic BP and 







































*CVD = Cardiovascular disease 







Table 33 (b): Percentage distribution of hypertensive DBP and various 







































*CVD = Cardiovascular disease 
**PVI = Peripheral vascular insufficiency 
 
Forty five patients (65.2%) having retinopathy had DBP >80 mm Hg 
followed by 23 (63.9%) who had CVD. 
 
Table 34: Percentage distribution of age group and diabetes management 
in T2DM subjects 
Variable 20-40 years 
41-60 
years 
























































Table 35: Percentage distribution of duration of Diabetes and diabetes 
management in T2DM subjects 
 


























































Table 36: Percentage distribution of BMI groups and diabetes 












































































3.2 Findings of Frequency of Chronic Complications: 
The frequency of diabetes complications, overall and between the genders 
is shown in Table A. The most frequently occurring metabolic abnormality 
was high HbA1c (89.9%), followed by hyperglycemia on the basis of FBG 
(88.3%), hypertriglyceridemia (70.0%) and obesity (60.5%).  
 
Table A: Frequency of Chronic Complications according to gender 
in all PDCs 











Hyperglycemia on the 
basis of FBG (>120 mg/dl) 
88.3 88.6 88.0 ns* 









































Obesity 60.5 53.8 67.2 0.008 
Microvascular complications 
Retinopathy 31.3 29.4 32.8 ns 
Nephropathy 22.6 28.6 16 0.059 
Peripheral Neuropathy 18.6 21.6 16 ns 
Diabetic Foot Ulcer 2.0 3.0 1.1 0.175 
Macrovascular complications 
Hypertension 59.0 56.2 62.0 ns 
Coronary Artery Disease 6.4 7.3 5.6 ns 












ns* = not significant 
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Among microvascular complications retinopathy was 31.3%, peripheral 
neuropathy was 18.6% and nephropathy 22.6%. Among macrovascular 
complication half of the subjects (59.0%) were hypertensive. Among 
females frequency of obesity (p=0.008) was significantly higher and 
among males frequency of hypertriglyceridemia (p=0.022) was 
significantly higher.  
 
The frequency of diabetes complication according to age showed that 
retinopathy (p=0.014), hypertension (p=0.001), cardiovascular disease 
(CVD) (p=0.010), and peripheral vascular insufficiency (PVI) (p=0.033), 
was significantly higher among the older group i.e. >45 years, shown 
below in Table B. 
 
The frequency of diabetes complication according to duration of diabetes 
showed that retinopathy (p=0.002), diabetic foot ulcer (p=0.004), 
coronary artery disease (p=0.000) and PVI (p=0.000) was significantly 
higher among those with longer duration of diabetes i.e.> 10 years, 
















Table B: Frequency of various chronic complications according to age. 
 
Chronic complications                 Age Group_______     
                                                                       
Metabolic variables 
 




Hyperglycemia on the 
basis of FBG (>120 mg/dl) 
89.8 87.6 ns* 
 

































Obesity (>25kg/m2) 61.9 60.5 ns 
 
Microvascular  Complications 
Retinopathy 15.9 35.0 0.014 
Nephropathy 13.8 24.6 ns 
Peripheral Neuropathy 17.6 18.8 ns 
Diabetic Foot Ulcer 2.4 1.8 ns 
Macrovascular Complications 
Hypertension 43.5 59.2 0.001 
Coronary Artery Disease 2.0 8.0 0.010 
Stroke - 0.2 ns 
Peripheral Vascular 
Insufficiency 
6.2 16.8 0.033 
Within age group 








Table C: Frequency of various chronic complications according to duration 
of T2DM in all PDCs 
 
 
Chronic complications        Duration of Diabetes_____      ___ 
 
                                                                                                                  
Metabolic variables 
≤10 yrs              
% 




Hyperglycemia on the 





































Obesity (>25kg/m2) 61.9 56.2 ns 
Microvascular Complications 
Retinopathy 26 49.1 0.002 
Nephropathy 19.2 33.3 0.066 
Peripheral Neuropathy 18.5 18.7 ns 
Diabetic Foot Ulcer 1.2 5.1 0.004 
Macrovascular Complications 
Hypertension 53.1 62.1 0.068 
Coronary Artery Disease 4.5 13.9 0.000 
Stroke - 0.7 ns 
Peripheral Vascular 
Insufficiency 
89.4 70.8 0.000 
Within duration of DM 











































4.1 METHODOLOGICAL DISCUSSION  
4.2 Discussion on the Findings of the Study 
Results of our study indicate that family physicians are not adequately 
following the 2004 ADA standards for comprehensive disease 
management of their patients with diabetes. This outcome is seen despite 
widespread awareness about diabetes and its preventive management by 
diabetologists at different peripheral diabetic clinics. We do not know if 
other diabetes clinics in the region have annual auditing of their medical 
records to assess the performance of the medical practitioners and their 
respective clinics.  
 
4.2.1 Compliance with ADA guidelines: 
Our study provides evidence that ADA guidelines were not been 
completely implemented in the four PDCs run by trained family physicians 
called diabetologists. The comorbidities and diabetes complications were 
frequent and patients with type 2 diabetes had poor glycemic control. 
Complex treatment regimens were necessary. In addition to metabolic 
outcomes, process measures are also important in good diabetes care. 
Screening rates in the patients with type 2 diabetes were not good, 
especially for eye examinations, microalbuminuria and lower extremities 
examination. Screening for BMI, blood pressure and lipid profiles were 
relatively better. All patients were not tested for diabetes complications 
during the study period and urine albumin screening was documented for 
only 25% of the patients.  
We found that screening of various metabolic measures at PDC1 was 
closer in compliance with ADA guidelines than the other three PDCs. 
However, none of the PDCs had complete documented medical records as 
several parameters were found missing in all. Apparent failure to meet 
ADA guidelines may reflect the true limitations of our practice, but 
analysis was based largely on data recorded by hand in patient medical 
records and may have underestimated actual performance.  
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In our study 18.4% subjects between 20-40 years of age had type 2 
diabetes. In Asian population this trend of occurrence of type 2 diabetes 
at a younger age is comparable to other studies. Mean age of males and 
females was younger as compared to Caucasians (44). The high 
prevalence of diabetes (66.1%) in the 41-60 age group meant that the 
majority of diabetics were suffering from the disease in their most 
productive years of life (53). Mean age of the diabetics in our study was 
51.4 ± 11.45 years for males and 50.5 ± 9.33 for females. The fact that 
60% subjects gave a positive family history of diabetes indicates a strong 
familial influence of the disease in our population. However, this could also 
be due to life style changes and inadequate physical activities among the 
population. 
We know that obesity is taken as a risk factor for diabetes and 
cardiovascular disease (54). In February 2000, the WHO Regional Office 
for the Western Pacific, the International Association for the Study of 
Obesity, and the International Obesity Task published provisional 
recommendations for adults in Asia-Pacific as overweight at BMI 
>23kg/m2 and obesity at BMI >25kg/m2 (49). According to the new 
recommendations 60.5% of our diabetic subjects were obese with a BMI 
>25 kg/m2 and among these (67.2%) females were more obese than their 
male counterpart.  Another study in our region has shown a similar 
pattern of obesity, hypertension and dyslipidemia among rural population 
of Pakistan (55).  
 
4.2.2 Glycemic control (HbA1c) 
Information about overall glycemic control in type 2 diabetic in Pakistan is 
lacking. Recommended ADA guidelines for glycemic control is HbA1c <7%   
and pre-prandial plasma glucose (or FBG) 80-120 mg/dl. In our study, 
ADA recommendations met in 40 (10.8%) patients who had FBG between 
80 -120 mg/dl and 10.15% had HbA1c of ≤7%. HbA1c of >7and ≤8% in 
14.6%, and >8% in 75.3% patients showed that the diabetic population 
coming to these PDCs had poor glycemic control of their diabetes. The 
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ADA recommendations for assessment of glycemic control are: Perform 
HbA1c at least two times/year in patients who are meeting treatment 
goals, and perform HbA1c quarterly in patients not meeting glycemic 
goals. Since we reviewed the medical records of those subjects who came 
to the PDCs at their first visit, therefore, we did not assess the above ADA 
recommendations. 
The mean values of HbA1c 9.13% found in our study are slightly higher 
than those observed in Bangladesh (HbA1c 8.01%) (54) and is closer to 
that found in India (HbA1c 9.3%) (56). About three-fourth (90%) of the 
subjects had poor glycemic control on their first visit to the PDCs and 
51.7% of them had diabetes between 2-10 years. This is indicative of 
early high tendency of diabetic complications due to poor glycemic control. 
In short, HbA1c values indicated that patients coming to the PDCs did not 
have their diabetes under optimal control.  
 
4.2.3 Lipid profiles 
Dyslipidemia is prevalent in diabetic patients and increases risk for 
atherosclerotic vascular disease (57, 58, 59). Dyslipidemia increases risk 
for artherosclerotic vascular disease in diabetic patients, and effective 
management has been shown to reduce secondary vascular events (58, 
59, 60). ADA guidelines recommend a LDL level ≤100 mg/dl. In our study, 
only 32% patients had documented LDL levels ≤100 mg/dl. Between 41-
60 years of age 71.3% patients had TC ≥200 mg/dl and 75% had 
LDL>130 mg/dl. Significantly higher triglycerides and low HDL which is 
typical of diabetes dyslipidemia were also seen in a study in India (53). 
We know that low HDL cholesterol is an independent risk factor for chronic 
heart disease. The overall high percentage (43.3%) of low HDL in our 
study shows similar evident of low HDL prevalence in Pakistani population 
in another study (55). Furthermore, only 15.6% patients with a diagnosis 
of dyslipidemia were at ADA goals. Though 75 patients had LDL value of 
>130 mg/dl of these only 17.3% were prescribed statin. This showed that 
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the comorbid conditions of dyslipidemia were not managed according to 
the ADA guidelines. 
 
4.2.4 Hypertension 
On the basis of ADA 2004 recommendations, blood pressure goal of 
≤130/80 was documented in 44.7% (265) patients. In our study 61.2% 
(363) of the patients had SBP in desired range and 49% (291) had DBP in 
desired range. Only 03 patients of the total sample of 691 met the 
recommended ADA treatment values of HbA1c level ≤7%, a blood 
pressure ≤130/80 mmHg and an LDL level ≤ 100 mg/dl.  BP >130/80 of 
mm Hg was found in 55.3% patients (145 men and 183 women). Blood 
pressure levels in the patients averaged 138/86 mmHg. Research has 
shown that lowering blood pressure to a mean of 144/82 mm Hg in 
hypertensive diabetic patients significantly reduced complications of 
macrovascular and microvascular disease and diabetes-related deaths 
(56, 61, 58, 59). 
Although the majority of patients in the study had blood pressure 
measured, of the total sample only 27% of patients were taking 
antihypertensive medications and met criteria for control. In the patients 
with a diagnosis of hypertension, only 19.7% were treated to the ADA 
goal. Family physicians were better at documenting blood pressure than 
lipid levels. 
 
4.2.5 Management of T2DM 
Our study showed that management of the comorbid conditions for 
hypertension and dyslipidemia was overall suboptimal but better 
compared to other diabetes management at the PDCs. ADA recommends 
that urine be tested annually for presence of Microalbuminuria. During 
their first visit, in view of this only 25% patients were screened for 
microalbuminuria. ADA recommends that dilated eye examination 
(fundoscopy) be performed shortly after diagnosis of diabetes and then 
annually. In our study 31% patients had eye examination at first visit. 
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Since we did not audit the medical records of these patients for annual 
reviews; we may assume that some of these patients had their annual 
screening tests and examinations during the annual review visits. Of the 
691 patients, 41% were on Aspirin; 20.3% on ACE inhibitors; 27% on 
anti-hypertensive; 15.6% on Statin and 22% on insulin injected twice a 
day. A high prescription rate of insulin was expected and this showed that 
the family physicians had implemented intensive management for good 
glycemic control to improve diabetes care in the community.  
It has been recommended that medical management to decrease 
cardiovascular risk should start when type 2 diabetes mellitus is diagnosed 
(62, 63). At the very least, medications proven to reduce cardiovascular 
risk should be prescribed for patients with diabetes and established 
atherosclerotic disease (64). In addition to smoking cessation and control 
of blood pressure, strategies proven to reduce cardiovascular risk in 
patients with diabetes and established atherosclerotic disease include 
therapy with antiplatelet agents, statins and angiotensin-converting 
enzyme (ACE) inhibitors (62). 
Only 74 patients between 41-60 years of age were on ACE therapy and 
remaining 331 patients were not on ACE medications. While ACE therapy 
prescribed to 62 out of 240 patients with high CVD risk and 104 out of 
328 patients with hypertension. We found that the use of all 3 types of 
agents (antiplatelet agents, ACE inhibitors and statins) proven to reduce 
cardiovascular risk was low in our study. This is indicative of poor 
compliance with ADA guidelines. 
Adhering to ADA recommendation for anti-platelet therapy, Acetylsalicylic 
acid i.e. aspirin was prescribed to patients only >21 years of age. In our 
study for primary prevention according to ADA guidelines, aspirin therapy 
in type 2 diabetes patients with increased CV risk was prescribed to: 
♦ Age > 40 (181 patients) 
♦ Family history of CVD (not documented in the medical records) 
♦ Hypertension (155 patients) 
♦ Smoking/tobacco consumption (21 patients) 
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♦ Dyslipidemia (148 patients) 
♦ Albuminuria (51 Patients) 
A survey of 104 physicians including 8 physicians with special interest in 
diabetes was conducted in Karachi. The aim was to assess current 
physician knowledge and practice of optimal and acceptable diabetes care. 
That study also showed suboptimal standard of diabetes care by the 
healthcare providers. (65)  
Although barriers to successful management by the family physicians is 
not known but could include lack of knowledge of current 
recommendations, patient compliance issues including medication cost 
and side effects, and lack of available diabetes educators (66). 
 
4.2.6 Chronic Complications: 
Among the individual PDCs, 74.1% patients were screened for HbA1c at 
PDC2 and 32% at PDC3. Poor glycemic control of patients with a mean 
value of HbA1c >9.5% was found in PDC4. Blood pressure screening of 
patients showed BP >130/80 mmHg more in PDC1 and less in PDC4. 
Prevalence of chronic complications found in screened patients is as 
follows: 40% retinopathy seen in PDC3; 71.4% nephropathy in PDC3; 
64.3% hypertension in PDC1; 91.4% dyslipidemia in PDC1; 10.7% CVD in 
PDC4, 0.5% stroke in PDC2; 20% peripheral neuropathy in PDC1 and 
15% peripheral vascular insufficiency in PDC1.  
Among the macrovascular complications in our study, overall rates of CVD 
were 6.4%, and stroke 0.16%. This pattern was similar to that reported 
from India (CVD was 11.4% and Stroke 0.9%) (56). A similar study 
conducted in Karachi reported higher rates of chronic complication than in 
our study (hypertension 46%, neuropathy 49% and CVD 28%) (67). In 
our study, the prevalence of peripheral vascular insufficiency was 14.5% 
and 2% patients had diabetic foot ulcers. This could be related to the 
social and cultural behavior of these subjects, particularly bare-foot 
walking. Furthermore, peripheral neuropathy found in 18.6% could 
aggravate the risk of injuries and foot ulceration. Nephropathy was seen 
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in 22.6% of patients. In our study the prevalence of retinopathy was 
31.3% other studies too have shown higher prevalence (53, 68, 69). The 
comorbidities are preventable, with evidence documenting that a 1% 
reduction in HbA1c can reduce the risk of myocardial infarction (MI) by 
16% (70); a 10 mmHg reduction in systolic BP could decrease all-cause 
mortality, MI, stroke and microvascular complications by 18%, 21%, 44% 
and 37%, respectively (71); and improving lipid profile can reduce the risk 
for coronary artery disease by 22%-55% (72) 
 
4.2.7 Frequency of chronic complications: 
This study also showed the pattern of diabetic complications and its 
associations with gender, age and duration of diabetes among type 2 
diabetic subjects in peripheral diabetes clinics. 
Obesity (67.2%), hypertension (53.2%) and retinopathy found to be 
higher in females while microvascular complications like nephropathy, 
peripheral neuropathy, and diabetic foot ulcers were more prevalent in 
males. Macrovascular complications like CVD and peripheral vascular 
insufficiency were also more in males than in females. 
Frequency of obesity and hyperlipidemia did not increase with age or 
duration of diabetes suggesting that for a large proportion of subjects 
these disorders could have appeared before the onset of diabetes i.e. 
during the impaired glucose period. The frequency of hypertension 
increased with age in those >45 years of age and 59.2% of these subjects 
were hypertensive. This close association of diabetes and hypertension is 
a well known phenomenon. (54, 56, 69, 63)  
In our study, the frequency of retinopathy, nephropathy, CVD and 
peripheral vascular insufficiency increased with age and duration of 
diabetes. This was also observed in other (73) studies in the Asian and 
Middle-East region. (74, 75) No difference in HbA1c level was evident 




4.3 METHODOLOGICAL CONSIDERATION  
4.3.1 Study Design  
In Pakistan more than 10% of the adult population suffers from diabetes. 
(76) The major diabetic complications include retinopathy, chronic heart 
disease, nephropathy, neuropathy, stroke, peripheral vascular disease and 
diabetic foot ulcer. Many of these complications, if not prevented and left 
untreated, can be fatal. All have the potential to reduce the quality of life 
of people with diabetes and their families. We also know that T2DM is a 
major risk factor for CVD and proper aggressive early treatment options 
can reduce this risk in such patients (77). It is well recognized that 
successful management of T2DM requires strict control of glycemia as well 
as of risk factors to prevent disease progression and many micro and 
macro-vascular complications (78, 79). Therefore, managing such type 2 
diabetes patients is a challenge that trained health professionals are 
required to deal with in their specialized medical field. Hence great 
responsibility lies with the trained health professionals to follow the 
diabetic management of their patients in a systemic and recommended 
manner to delay or prevent serious macro and microvascular 
complications. This in return can help to reduce the economic and 
emotional burden of diabetes and morbidity and mortality among the 
population.  
Keeping these views in our mind, we designed a study to learn the 
compliance of ADA guidelines by family physicians at their clinics. We also 
wanted to know the quality of diabetes care given and prevalence of 
chronic complications in type 2 diabetics at the PDCs. 
 
4.3.2 Retrospective Cross sectional study  
In our retrospective study we audited medical records of patients for 
research. Six hundred and ninety-one medical records of registered type 2 
diabetics from four PDCs were audited. Such data collection can enable 
vast numbers of people to be entered into a study prospectively or 
retrospectively. They can be used to construct a cohort, to produce a 
 96
sample for a cross sectional study, or to identify people with certain 
conditions or outcomes and produce a sample for a case controlled study 
(80). As a group cross sectional studies are descriptive studies that can be 
used for testing hypotheses. They are used in surveys of various types 
and for measuring prevalence. Prevalence equals the number of cases in a 
population at a given point in time. In cross sectional studies all 
observations are made on a single occasion. Prevalence is vitally 
important to the clinician because it influences considerably the likelihood 
of any particular diagnosis and the predictive value of any investigation. 
They are usually carried out on the general population and disease can be 
classified by personal characteristics like age, sex, race, education, 
socioeconomic status and time or place. Cross sectional studies are also 
useful for describing the clinical spectrum of a disease, e.g., diabetes 
maybe used to study proportion who has retinal, renal or cardiovascular 
complications. Cross sectional studies look at outcome and exposure at 
the same time.  
The advantage of such studies is that subjects are neither deliberately 
exposed, treated, or not treated and hence there are seldom ethical 
difficulties. Only one group is used, data are collected only once and 
multiple outcomes can be studied; thus this type of study is relatively 
cheap. Many cross sectional studies are done using questionnaires. 
Alternatively each of the subjects may be interviewed. A census is another 
example of a cross sectional study. 
 
Cross sectional studies (Key points) 
• Cross sectional studies can determine prevalence 
• Are relatively quick and cheap 
• Fewer resources required 





During a retrospective cross sectional study design a number of problems 
may arise that may invalidate the results unless they are properly 
handled.  
 
4.3.3 Strength of the Study 
Our study was a primary healthcare based study focusing on patients 
coming to peripheral diabetes clinics in different townships of Karachi. The 
clinics provided easiest selection of samples with remote chances of 
misdiagnosis with other non communicable diseases and this gives validity 
of diagnosis. There was relative homogeneity of the sample in terms of 
access to health care. Because the data were recorded in medical records, 
use of this information eliminated the potential for recall bias and 
increased the reliability of the data. 
 
4.3.4 Weakness of the Study  
The study has several limitations. We consider that our conclusions are 
based on the auditing of the documented medical records of T2DM coming 
to the PDCs. However, the FPs may have been more thorough in their 
examinations and management than is noted in the medical records of the 
patients. It is to be remembered that documentation is increasingly 
considered a valid substitute for what was actually asked or done. At the 
PDCs physicians were often reminded and encouraged to keep accurate 
and updated medical notes. In the past, medical records from PDCs were 
not audited and the performance of the physicians and their clinics not 
evaluated.  
Information collected such as laboratory test results, blood pressure, 
monofilament examination, and presence of comorbid conditions should 
be complete and reliable. There is a limitation to the reliability of results of 
review of medical records when these records have incomplete 
documentation. Other limitations of our study included its retrospective 
nature and we agree that a prospective manner of data collection would 
have given strength to reliability of the findings. In some cases, 
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complications noted in the problem list could not be confirmed with the 
limited data available. Data on level of income and education were not 
collected.  
If a sample is used, it is essential to ensure that the subjects included in 
the sample are representative of the population being investigated. The 
T2DM population targeted during our study was not representative of the 
whole population as it included those patients who could afford treatment 
at these private PDCs. Those type 2 diabetics who cannot financially afford 
treatment either go to government health facilities, charitable health 
clinics or to other local healers in their locality. Our results maybe 
population specific and biased toward those patients who had resources 
that permitted more visits per year. This is reflected as during the study 
period, 492 (71.2%) visited the PDCs only once and 199 (28.8%) visited 
more than once. Out of 691 patients only 8 had their annual review and 
those findings at annual review were not included in the study. 
Another limitation is the lack of data on the prevalence of hypoglycemia. 
Although we believe that severe hypoglycemia is uncommon in our 
patients, many patients using sulfonylureas or insulin report intermittent 
glucose levels of 54 mg/dl (3 mmol/l). We found one patient had FBG 60 
mg/dl but it was not mentioned whether symptoms of hypoglycemia were 
present. Waist-Hip ratio was not measured and is not clinically common in 
medical practice of family physicians. Some PDCs were better equipped 
with basic health facilities than others – this may have given them undue 
advantage over their individual performance.  This lack of infrastructure 
can be attributable to no lower leg examinations performed at two PDCs. 
No diabetes education or dietary counseling and nor self-monitoring of 
blood glucose (SMBG) was recorded. Furthermore, Ultrasound Doppler 
test and Ankle Brachial Index (ABI) are performed to help in diagnosis of 







Our data shows that most medical records of the patients that visited the 
different PDCs were inadequately filled and lacked proper documentation. 
Screening evaluations recommended by ADA guidelines for early detection 
of diabetes complications were suboptimal in the PDCs.  
In our part of the world, we generally have a culture of not documenting 
medical information as required in medical records or forms in the 
healthcare centers. Poor record maintenance shown in our study may 
signify the importance of periodic auditing of medical records and forms at 
healthcare centers in order to assess quality of diabetes primary care 
given to the patients. 
The study showed poor glycemic control despite a younger population and 
shorter duration of diabetes. Fewer patients were screened for detection 
of diabetes management and chronic complications. Many patients 
screened for diabetes complications were found to have more than one 
complication. The high prevalence of diabetes complications can 
contribute to economic burden of the disease on the patients and their 
families.   
We found that obesity, poor glycemic, blood pressure and lipid control can 
be contributing causes to the increase frequency of chronic diabetes 
complications among our patients.  
Since complications are already present at diagnosis, this indicates late 
diagnosis.  
In short, a wide gap seems to exist between effective diabetes 
management practices and their implementation. The study strongly 
suggests the need for developing interventions targeted at patients, 
healthcare providers and other stakeholders for improving the quality of 
diabetes care. 
 
The quality of diabetes care generally imparted was suboptimal and based 





1. The primary management goals of diabetes are to reduce the 
prevalence or worsening of chronic complications of diabetes. In this 
regard, frequency of testing, especially for patients with suboptimal 
control, needs improvement. 
 
2. Strategies to improve family physicians compliance with documenting 
screening and management of dyslipidemia and hypertension in diabetic 
patients are needed. 
 
3. We suggest that inexpensive quality care should be provided to the 
patients who largely come from low resource and underserved 
communities. This can be done one way by giving discount rates for 
laboratory tests and medications. 
 
4. Our findings suggest a need for interventions to improve healthcare 
provider compliance with ADA guidelines. In addition, improved patient 
access to diabetic educators could benefit family physicians.  
 
5. Interventions targeted at primary care providers’ office staff may be 
more fruitful than those targeted solely at physicians. There is also a need 
for use of non-physician providers to perform some examinations like foot 
inspection and use of protocols. 
 
6. Public health resources should be focused on identifying ways to 
improve the efficacy of patient-physician partnerships aimed at achieving 
practice recommendations. 
 
7. Further research is needed to determine barriers to successful diabetes 
management by healthcare providers so that alternative strategies can be 
implemented and tested. 
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4.6 FUTURE RESEARCH IMPLICATIONS 
 
1. We need large scale and cost-effective prevention programs to improve 
primary diabetes care in low resource and underserved communities as 
well as to reduce the cost of diabetes in Pakistan. One way of achieving 
this can be through international collaboration with the aims at improving 
health care delivery through setting up diabetes clinics and training of 
health care providers.  
 
2. Similar projects like the one between World Diabetes Foundation (WDF) 
and BIDE are needed nationally in order to improve primary healthcare 
delivery. Under this project more than 75 doctors will participate in a 1-
year specialized training course in diabetes and its management. After the 
course each of the trained doctors is expected to start a 
peripheral diabetes clinic (82). The project duration is from Nov 2007 to 
Nov 2010. During this three years period a prospective study can be done 
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